---

FAT June 2026 - Comprehensive DNB Answers

---

QUESTION 1: Coagulation Cascade, Coagulation Pathways & Recent ASRA Guidelines

A. Coagulation Cascade

Cell-Based Model of Hemostasis (Modern Understanding)

PHASE 1: INITIATION
─────────────────────────────────────────────────────
Tissue damage → Tissue Factor (TF) exposed on subendothelial cells
TF + VIIa → TF-VIIa complex (Extrinsic tenase)
         ↓
    Xa + IIa (small amounts) → activates platelets
         ↓
    Va formed on platelet surface

PHASE 2: AMPLIFICATION
─────────────────────────────────────────────────────
Small amounts of thrombin (IIa) → amplify the signal:
  - Activates platelets (GpIb binding)
  - Activates cofactors V, VIII
  - Activates XI on platelet surface
  - Cleaves vWF → releases FVIII

PHASE 3: PROPAGATION
─────────────────────────────────────────────────────
Platelet surface: IXa + VIIIa → Intrinsic tenase complex
Intrinsic tenase → large amounts of Xa
Xa + Va → Prothrombinase complex
Prothrombinase → THROMBIN BURST (large amounts)
Thrombin → Fibrinogen → Fibrin
Thrombin → XIIIa → Cross-linked stable fibrin clot

---

Classical Coagulation Cascade (Exam Diagram)

EXTRINSIC PATHWAY          INTRINSIC PATHWAY (Contact)
────────────────           ─────────────────────────────
Tissue Factor + VII        XII → XIIa
       ↓                   XI  → XIa
     VIIa                  IX  → IXa
       ↓                       ↓
   (+ Ca²⁺ + PL)          IXa + VIIIa + Ca²⁺ + PL
       ↓                       ↓
       X ──────────────────→  Xa
              COMMON PATHWAY
                    ↓
           Xa + Va + Ca²⁺ + PL
           (Prothrombinase complex)
                    ↓
         Prothrombin (II) → Thrombin (IIa)
                    ↓
         Fibrinogen (I) → Fibrin → Cross-linked Fibrin (XIII)

---

Coagulation Inhibitors

• TFPI (Tissue Factor Pathway Inhibitor) - inhibits TF-VIIa-Xa complex
• Antithrombin III - inhibits thrombin, Xa, IXa (enhanced by heparin)
• Protein C + S - inhibit Va and VIIIa
• Plasminogen → Plasmin - fibrinolysis (tPA activates)

---

B. ASRA Guidelines (2022) - Key Points for Regional Anesthesia & Anticoagulation

Neuraxial Anesthesia - Time Intervals

Key ASRA 2022 Updates

1. DOACs - time interval is renal function-dependent (check CrCl for dabigatran)
2. Anti-Xa monitoring recommended for LMWH in special populations
3. Peripheral nerve blocks - shorter intervals acceptable vs neuraxial (lower risk)
4. Ultrasound guidance reduces risk, but does NOT eliminate anticoagulation concerns for deep blocks (paravertebral, lumbar plexus, celiac)
5. Catheter removal follows same rules as needle placement

ASRA Risk Stratification

HIGH RISK blocks (same rules as neuraxial):
  - Lumbar plexus (psoas compartment)
  - Paravertebral
  - Retroperitoneal

MODERATE RISK (shorter intervals may apply):
  - Deep: popliteal sciatic, femoral, infraclavicular

LOW RISK:
  - Superficial: interscalene, axillary, saphenous, ankle

• Miller's Anesthesia, 10e - PLASMA-MEDIATED HEMOSTASIS
• Barash Clinical Anesthesia, 9e - Coagulation Cascade Inhibitory Control

---

QUESTION 2: Cleft Palate - Anesthetic Considerations

Introduction

---

Preoperative Assessment

History & Examination

• Age at surgery: Lip - 3 months (rule of 10s); Palate - 6-18 months
• Syndromic associations: Screen for associated cardiac defects (VSD in 22q11), airway abnormalities
• Nutritional status: Feeding difficulties, weight gain
• Airway assessment: Retrognathia, macroglossia, limited mouth opening, glossoptosis (Pierre Robin)
• URTI: Postpone for 2-4 weeks if active URTI (high airway secretions + reflexes)

Investigations

• Hb, CBC - anemia assessment (minimum Hb 10 g/dL - rule of 10s)
• Coagulation profile
• Echocardiography if cardiac defect suspected

---

Airway - The Critical Issue

DIFFICULT AIRWAY ANTICIPATED IN:
─────────────────────────────────
Pierre Robin Sequence:
  → Micrognathia + Glossoptosis + U-shaped cleft

Treacher Collins:
  → Malar hypoplasia + Micrognathia + Limited mouth opening

Stickler Syndrome:
  → Midface hypoplasia

• Awake fiberoptic if severe airway concern (older cooperative child)
• Inhalation induction (sevoflurane) preferred - maintains spontaneous ventilation
• RAE (Ring-Adair-Elwyn) preformed oral tube used - exits midline at chin, away from surgical field
• Pack throat with moist gauze (to prevent blood/secretions reaching larynx)
• Dingman mouth gag is placed by surgeon - may dislodge tube (recheck position after gag placement)
• Have difficult airway cart ready

---

Intraoperative Management

SETUP:
Patient supine, shoulder roll, neck extended (slight)
Surgeon at head, anesthesiologist at foot or side

TECHNIQUE:
- ETT (oral RAE) + throat pack
- IPPV
- Cuffed tubes preferred (age >8 yr) / uncuffed with leak (infants)
- Temperature monitoring (prone to hypothermia)
- Warm fluids, warm blankets

ANALGESIA (Multimodal):
- Intraoperative: IV fentanyl / morphine
- Nerve blocks:
    • Infraorbital nerve block (lip repair) - reduces opioid need
    • Greater palatine nerve block (palate repair)
- IV paracetamol
- Avoid NSAIDs < 6 months

AVOID:
- Succinylcholine (if difficult intubation - keep option)
- N₂O (bowel distension, increases incidence of PONV)

---

Postoperative Considerations

Airway Protection

• Extubate awake (not deep) - risk of obstruction post-palate repair
• Post-op tongue stitch (traction suture) placed by surgeon to pull tongue forward in Pierre Robin
• Supine + lateral (recovery) position - allows drainage
• NEVER insert nasopharyngeal airway (disrupts repair)
• 24-48 hr monitoring for airway obstruction

Pain Management

• Regular paracetamol + opioid PRN
• Arm restraints prevent child touching suture line

PONV

• High risk - prophylaxis with ondansetron + dexamethasone
• Avoid opioids where possible

Potential Complications

---

Flowchart: Anesthetic Management of Cleft Palate

Preop Assessment
      ↓
  Syndrome? → YES → Airway MDT, Echo, Genetic review
      ↓ NO
  Airway Assessment
      ↓
Simple cleft     Pierre Robin / Complex
      ↓                    ↓
Inhalation        Awake FOB or gas induction
induction         with backup plan
      ↓
Oral RAE tube + Throat pack
      ↓
Confirm position after Dingman gag insertion
      ↓
Maintenance: Sevo/iso + air/O₂
Multimodal analgesia (nerve blocks + IV paracetamol)
      ↓
Extubate AWAKE, lateral position
      ↓
Monitored recovery ≥24 hr

• Barash Clinical Anesthesia, 9e
• Cummings Otolaryngology, Chapter 44

---

QUESTION 3: Brachial Plexus - Diagram & Approaches for Shoulder Surgery

A. Brachial Plexus Anatomy

Formation

ROOTS:         C5 - C6 - C7 - C8 - T1
                 ↓
TRUNKS:       Upper (C5,C6) - Middle (C7) - Lower (C8,T1)
                 ↓
DIVISIONS:    Anterior (3) and Posterior (3)
                 ↓
CORDS:        Lateral - Posterior - Medial
              (named relative to axillary artery)
                 ↓
BRANCHES/TERMINAL NERVES:

MNEMONIC: "My Teeth Deserve Constant Brushing"
 Musculocutaneous - Terminal nerves of lateral cord
 Thoracodorsal     - From posterior cord
 Dorsal scapular   - From C5 root
 Circumflex (axillary) - From posterior cord
 Branches of medial cord

TERMINAL BRANCHES (5):
  Musculocutaneous (C5-C7)  - Lateral cord
  Median (C6-T1)            - Lateral + medial cords
  Ulnar (C8-T1)             - Medial cord
  Radial (C5-T1)            - Posterior cord
  Axillary (C5-C6)          - Posterior cord

Brachial Plexus Diagram

VERTEBRAE    ROOTS    TRUNKS    DIVS    CORDS      TERMINAL NERVES

C5 ──────────────────────────────────────────────► Musculocutaneous
          ╲           Upper ─── Ant ─╮
C6 ──────── ╲─────────/         ╰── Lateral cord ─► Median (lateral head)
              ╲                 Post─╮
C7 ──────────── Middle ─────────────► Posterior cord ─► Radial
              ╱                 Post─╯                  Axillary
C8 ──────── ╱─────────Lower── Ant ─╮
          ╱                   ╰── Medial cord ──► Median (medial head)
T1 ──────────────────────────────────────────────► Ulnar
                                                    Med. cutaneous
                                                    (arm & forearm)

---

B. Approaches for Shoulder Surgery

1. Interscalene Block (ISB) - GOLD STANDARD for Shoulder

• Patient supine, head turned 45° away
• US probe: transverse at cricoid level
• Identify SCM, anterior scalene, middle scalene
• Plexus appears as "traffic light" - hypoechoic circles between scalenes
• Needle: in-plane, lateral to medial
• Volume: 15-20 mL (0.5% ropivacaine / 0.5% bupivacaine)

• Phrenic nerve palsy - 100% ipsilateral (contraindicated in contralateral phrenic palsy, severe COPD, FEV1 < 1L)
• Horner's syndrome (30%)
• Recurrent laryngeal nerve block
• Intravascular injection (vertebral artery, carotid)
• Epidural/intrathecal spread
• Pneumothorax (0.2%)

2. Supraclavicular Block

• "Spinal anesthesia of the arm"
• Good for shoulder and upper arm but inconsistent coverage of shoulder joint itself (misses suprascapular)
• US guided - higher risk of pneumothorax (1-6% landmark, <1% US)

3. Suprascapular Nerve Block

• Innervates 70% of shoulder joint (superior + posterior capsule)
• Used as adjunct or when ISB contraindicated
• Combine with axillary nerve block for complete shoulder coverage
• Lower complication profile vs ISB (no phrenic nerve palsy)

4. Infraclavicular Block

• Covers upper arm, elbow, forearm, hand (less reliable for shoulder)
• Less risk of phrenic palsy vs ISB

Comparison Table for Shoulder Surgery

Key ASRA Points for Shoulder Block

• ISB is preferred for major shoulder surgery (arthroplasty, large rotator cuff)
• Suprascapular + axillary nerve block is an alternative when phrenic nerve palsy unacceptable
• Ultrasound guidance is standard of care
• Single-shot vs continuous catheter for prolonged analgesia
• Morgan & Mikhail, 7e - Interscalene Block
• Barash Clinical Anesthesia, 9e - Table 51-2

---

QUESTION 4: Anesthetic Management for Robotic Prostate Surgery (RARP)

Introduction

1. Steep Trendelenburg position (30-40°)
2. Pneumoperitoneum (CO₂ insufflation)
3. Limited intraoperative access to patient
4. Prolonged operative duration (3-6 hours)

---

Preoperative Assessment

• Prostate cancer staging, PSA
• Cardiorespiratory reserve (critical - steep Trendelenburg stresses both systems)
• IOP risk factors: glaucoma, optic neuropathy (increased IOP is a major RARP concern)
• BMI - obesity worsens Trendelenburg effects
• Anticoagulants - stop per ASRA guidelines
• CPAP/BIPAP use (OSA)

• Raised ICP
• Severe glaucoma
• Severe GERD (relative)
• Morbid obesity (relative - still done but challenging)

---

Anesthetic Technique

General Anesthesia (Mandatory)

• ETT with IPPV (not LMA - aspiration risk in steep Trendelenburg)
• Total IV anesthesia (TIVA) preferred by many centers - smooth maintenance, less PONV
• Alternatively: volatile agent + opioid

• Propofol + fentanyl/remifentanil + rocuronium
• Rapid sequence if BMI >35 or GERD

• Propofol infusion or sevoflurane/desflurane in air/O₂
• Remifentanil infusion (excellent for steep Trendelenburg - easily titrated)
• Sugammadex for reversal (preferred over neostigmine - complete reversal)

---

Intraoperative Monitoring & Lines

• Standard ASA monitoring
• Invasive arterial line: strongly recommended (beat-to-beat BP monitoring, ABG for CO₂)
• 2 large-bore IVs
• Foley catheter (surgeon places intraoperatively)
• End-tidal CO₂ - will increase significantly with pneumoperitoneum; increase MV
• Temperature monitoring + active warming (hypothermia risk in prolonged cases)
• BIS or depth of anesthesia monitoring recommended

---

Positioning Considerations

STEEP TRENDELENBURG (30-45°) + PNEUMOPERITONEUM EFFECTS:
──────────────────────────────────────────────────────────

RESPIRATORY:
  ↑ IAP + Trendelenburg → ↑ Peak airway pressure (PAP)
  Diaphragm displaced cephalad → Atelectasis, V/Q mismatch
  FRC decreases → Desaturation risk
  SOLUTION: PEEP 5-8 cmH₂O + Recruitment maneuvers
            Accept higher PAP (up to 30-35 cmH₂O) to maintain oxygenation

CARDIOVASCULAR:
  Initial: ↑ Venous return → ↑ Preload → ↑ CO
  Prolonged: Venous pooling in upper body → ↑ Cerebral congestion
  Pneumoperitoneum: ↑ SVR, ↓ CO (abdominal compartment)
  SOLUTION: Vasopressors (phenylephrine/norepinephrine) for hypotension
            Cautious fluid (not excessive - cerebral edema, airway edema)

OCULAR:
  ↑ IOP (from 15 → 25-40 mmHg during case)
  Risk of POVL (Postoperative Visual Loss) - rare but catastrophic
  SOLUTION: Avoid prolonged extreme Trendelenburg
            Check eyes periodically
            Avoid direct pressure on eyes
            Goal: case completion < 4-5 hours in high-risk patients

AIRWAY EDEMA:
  Prolonged head-down + large fluid → periorbital/laryngeal edema
  SOLUTION: Extubate awake, consider leak test before extubation
            If no leak: consider delayed extubation or nebulized adrenaline

NEUROLOGICAL:
  ↑ ICP (Trendelenburg + CO₂ absorption)
  Caution in patients with raised ICP

---

Pneumoperitoneum Effects

---

Fluid Management

• Restrictive strategy (goal-directed): 500-1000 mL total; avoid overloading
• Rationale: Reduces bowel edema, airway edema, periorbital edema
• Use vasopressors to maintain MAP rather than fluid loading
• Blood loss is typically low (< 200 mL) - major advantage of robotic approach

---

Pain Management (Multimodal)

• Intraoperative: Remifentanil infusion
• Port sites: Local infiltration (surgeon)
• IV paracetamol + ketorolac intraoperatively
• Post-op: PO analgesics (paracetamol + tramadol ± celecoxib)
• TAP block or rectus sheath block for port-site pain
• Opioid-sparing preferred

---

Postoperative Considerations

• Monitor for CO₂ retention in recovery
• Sore throat (common - ETT + Trendelenburg)
• Shoulder tip pain (diaphragmatic CO₂ irritation) - reassure, self-limiting
• Early mobilization (ERAS protocol)
• DVT prophylaxis: LMWH + TED stockings

---

Flowchart: RARP Anesthetic Management

Preoperative
  ↓
Assess IOP risk, cardiac reserve, BMI
  ↓
GA + ETT (IPPV mandatory)
Art line + 2 IVs
  ↓
Induction: Propofol + Remi + Rocuronium
  ↓
Position: Steep Trendelenburg + lithotomy
Check ALL pressure points, eye protection
  ↓
Pneumoperitoneum established
↑ ETCO₂ → ↑ MV; ↑ PAP → accept, add PEEP
  ↓
Maintenance: TIVA or Volatile
Vasopressors for hypotension
Restrictive fluids
  ↓
Robot docked - NO ACCESS to patient
Ensure all lines secure, eyes protected, pressure points padded
  ↓
Emergence: Reverse NMB (Sugammadex)
Awake extubation, check for airway edema
  ↓
Recovery: Analgesia, PONV prophylaxis, early mobilization

• Barash Clinical Anesthesia, 9e - Laparoscopic and Robotic Prostatectomy
• Miller's Anesthesia, 10e - Key Points, Robotic Radical Prostatectomy

---

QUESTION 5: Local Anesthetics - Classification & Mechanism of Action

Classification

Chemical Classification

LOCAL ANESTHETICS
        ↓
    Linkage
   ↙         ↘
ESTER        AMIDE
(-CO-O-)     (-CO-NH-)
    ↓              ↓
PABA metabolite  Liver metabolism
Allergic++       Allergy rare

ESTERS:              AMIDES:
───────────          ───────────
Cocaine              Lidocaine (Lignocaine)
Procaine             Bupivacaine
Chloroprocaine       Levobupivacaine
Benzocaine           Ropivacaine
Tetracaine           Mepivacaine
(Amethocaine)        Prilocaine
                     Articaine
                     Etidocaine

MNEMONIC for AMIDES: "I Like Bupivacaine, More Please, Articulate Elegantly"
(lidocaine, levobupivacaine, bupivacaine, mepivacaine, prilocaine, articaine, etidocaine)

---

Classification by Clinical Duration

Classification by Potency (lipid solubility)

• Low potency: Procaine, chloroprocaine
• Intermediate: Lidocaine, mepivacaine
• High potency: Bupivacaine, ropivacaine, tetracaine

---

Mechanism of Action

Primary Mechanism: Voltage-Gated Sodium Channel Blockade

NORMAL ACTION POTENTIAL:
At rest → Na⁺ channels CLOSED (resting state)
Stimulus → Na⁺ channels OPEN → rapid Na⁺ influx → depolarization
After depolarization → Na⁺ channels INACTIVATED
Recovery → return to resting (closed) state

LOCAL ANESTHETIC ACTION:
LA (base form, unionized) → crosses lipid membrane
LA (ionized, protonated in cytoplasm)
  ↓
Binds intracellularly to INNER ASPECT of Na⁺ channel
  (specifically the α-subunit, segment 6 of domain IV)
  ↓
Na⁺ channel BLOCKED → Na⁺ cannot enter
  ↓
Membrane stabilized → No depolarization
  ↓
ACTION POTENTIAL PROPAGATION FAILS
  ↓
NERVE CONDUCTION BLOCKED

State-Dependent Blockade (Phasic/Use-Dependent Block)

• LAs preferentially bind to open and inactivated states of Na⁺ channel
• Rapidly firing neurons (pain fibers) are more susceptible
• This is why LA effect is enhanced with repeated stimulation

---

Ionization and the Henderson-Hasselbalch Concept

pH = pKa + log [base]/[acid]

At physiological pH (7.4):
  Low pKa drug → more un-ionized (base) → faster onset
  High pKa drug → more ionized → slower onset

pKa Values:
  Lidocaine:    7.9  → moderately fast onset
  Bupivacaine:  8.1  → intermediate onset
  Chloroprocaine: 8.7 → slower (but diluted = fast clinically)
  Mepivacaine:  7.6  → fastest onset (closest to pH 7.4)

ACIDIC TISSUE (infection/abscess, pH < 7.0):
  More ionized form → Cannot cross membrane → LA FAILS
  Clinical: Do NOT inject LA into infected tissue
  Management: Systemic analgesia + IV antibiotics first

---

Differential Nerve Block (Order of Blockade)

SENSITIVITY ORDER (small before large, myelinated before unmyelinated):

 B fibers (autonomic preganglionic) ─── FIRST BLOCKED
 C fibers (pain, temperature, unmyelinated) ─── EARLY BLOCKED
 Aδ fibers (sharp pain, temperature) ─── BLOCKED
 Aβ fibers (touch, pressure) ─── LATER
 Aα fibers (motor, proprioception) ─── LAST BLOCKED

CLINICAL SEQUENCE IN SPINAL/EPIDURAL:
  1. Sympathetic block (vasodilation, temperature change) - highest level
  2. Loss of pain and temperature
  3. Loss of touch and pressure
  4. Motor block - lowest level

Sympathetic > Sensory > Motor block
Sympathetic regresses last → Post-spinal hypotension risk persists

---

Physicochemical Properties

---

Systemic Toxicity (LAST - Local Anesthetic Systemic Toxicity)

CNS (lower threshold than CVS):
  Perioral tingling → Metallic taste → Tinnitus
  → Anxiety/confusion → Tonic-clonic seizures → CNS depression
  → Respiratory arrest

CVS (at higher doses):
  PR prolongation → QRS widening → Ventricular arrhythmias
  → Cardiovascular collapse
  Bupivacaine: cardiac toxicity > lidocaine (sodium + potassium channel block)

MANAGEMENT OF LAST:
  1. Stop injection IMMEDIATELY
  2. Call for help
  3. 100% O₂, maintain airway
  4. Treat seizures: Benzodiazepines (NOT propofol in high doses - too cardiac depressant)
  5. LIPID EMULSION THERAPY (Intralipid 20%)
     - Bolus: 1.5 mL/kg over 1 min
     - Infusion: 0.25 mL/kg/min
     - Repeat bolus once if persistent arrest
     - Max: 10 mL/kg in first 30 min
  6. CPR if cardiac arrest (prolonged - 60-90 min for bupivacaine)
  7. Avoid vasopressin, β-blockers, calcium channel blockers
  8. Consider ECMO if refractory

---

Vasoconstrictor Additives

• Adrenaline 1:200,000 (5 mcg/mL):
  • ↑ Duration (vasoconstriction delays absorption)
  • ↓ Peak plasma concentration
  • Marker of intravascular injection (↑ HR by >20 bpm)
  • Avoid in: ring blocks, digital nerves, penile block, end-arteries

---

QUESTION 6A: Non-Cardiogenic Pulmonary Edema (NCPE)

Definition

Starling's Equation (Edema Formation)

Fluid flux (Jv) = Kf[(Pc - Pi) - σ(πc - πi)]

Where:
  Kf = filtration coefficient (capillary permeability)
  Pc = capillary hydrostatic pressure
  Pi = interstitial hydrostatic pressure
  σ = reflection coefficient
  πc = capillary oncotic pressure
  πi = interstitial oncotic pressure

CARDIOGENIC EDEMA: ↑ Pc (↑ LVEDP → ↑ pulmonary venous pressure)
NON-CARDIOGENIC EDEMA: ↑ Kf (↑ permeability) or ↓ πc (↓ oncotic pressure)

Causes of NCPE

NCPE
 ├── ↑ CAPILLARY PERMEABILITY (most common)
 │    ├── ARDS (sepsis, pneumonia, aspiration, polytrauma)
 │    ├── TRALI
 │    ├── Neurogenic pulmonary edema (↑ ICP, seizures, head injury)
 │    ├── Reperfusion injury (post-cardiopulmonary bypass)
 │    ├── High altitude pulmonary edema (HAPE)
 │    └── Drug-induced (heroin, salicylate overdose)
 │
 ├── ↓ ONCOTIC PRESSURE
 │    ├── Hypoalbuminemia (cirrhosis, nephrotic, malnutrition)
 │    └── Massive crystalloid infusion
 │
 ├── NEGATIVE PRESSURE PULMONARY EDEMA (NPPE)
 │    ├── Acute upper airway obstruction (post-extubation laryngospasm)
 │    ├── Mechanism: Huge negative intrathoracic pressure → ↑ venous return + ↑ LV afterload
 │    └── Management: PEEP/CPAP; self-limiting in most cases
 │
 └── LYMPHATIC INSUFFICIENCY
      └── Post-lung transplant

Clinical Features

• Acute onset dyspnea, cough, hypoxia
• Frothy white/pink sputum (not always present)
• Bilateral crackles
• CXR: Bilateral infiltrates (butterfly pattern) without cardiomegaly
• SpO₂ low, unresponsive to O₂ alone (shunt physiology in ARDS)
• No elevated JVP, no S3, no peripheral edema (unlike cardiogenic)

Diagnosis

• BNP/NT-proBNP: low in NCPE (diagnostic separation)
• PCWP: <18 mmHg (Swan-Ganz or POCUS-estimated)
• ECHO: Normal LV function, no mitral valve disease
• Berlin Definition for ARDS (a major cause of NCPE):
  • Onset within 1 week of known clinical insult
  • Bilateral opacities on CXR/CT
  • Not fully explained by heart failure or fluid overload
  • PaO₂/FiO₂ ≤ 300 (mild), ≤200 (moderate), ≤100 (severe)

Management

NCPE MANAGEMENT ALGORITHM:
  ↓
AIRWAY & BREATHING:
  O₂ therapy (high flow initially)
  CPAP/BiPAP (NIV) for moderate cases
  Intubation + IPPV if: SpO₂ <88% despite NIV, respiratory fatigue, 
                        hemodynamic instability, consciousness ↓
  LUNG PROTECTIVE VENTILATION (for ARDS):
    Tidal volume: 6 mL/kg IBW (LOW - reduces VALI)
    Plateau pressure: ≤30 cmH₂O
    PEEP: Adequate (guided by FiO₂/PEEP table or esophageal pressure)
    FiO₂: Minimum to maintain SpO₂ 88-95%
    Permissive hypercapnia acceptable (pH > 7.20)
  ↓
CIRCULATION:
  Judicious fluid management (restrictive - not dry)
  Vasopressors (noradrenaline) for septic shock
  ↓
TREAT UNDERLYING CAUSE:
  Antibiotics (pneumonia/sepsis)
  Stop offending transfusion (TRALI)
  Head-up positioning (neurogenic)
  Descend altitude (HAPE)
  ↓
ADJUNCTS (for severe ARDS):
  Prone positioning (>16 hrs/day) - PaO₂/FiO₂ < 150
  Neuromuscular blockade (cisatracurium - 48 hr, moderate/severe)
  Inhaled NO or prostacyclin (pulmonary vasodilator - refractory)
  ECMO (salvage, PaO₂/FiO₂ < 80)

---

QUESTION 6B: TRALI (Transfusion-Related Acute Lung Injury)

Definition (Updated 2019 Consensus)

• Hypoxia (PaO₂/FiO₂ < 300 or SpO₂ <90% on room air)
• Bilateral pulmonary infiltrates on CXR
• No pre-existing ALI before transfusion
• No circulatory overload (TACO excluded)
• No alternative risk factor for ALI (Type I TRALI)

---

Pathophysiology

Two-Hit Model (Most Accepted)

HIT 1 (Patient factor - "priming"):
  Surgery, sepsis, trauma, shock → Activated neutrophils
  Primed PMNs adhering to pulmonary endothelium
  Damaged endothelium (susceptible)
         ↓
HIT 2 (Transfusion factor - "trigger"):
  ┌──────────────────────────────────────────────┐
  │ IMMUNE MECHANISM (Type I - ~80% cases):       │
  │ Donor HLA class I/II antibodies               │
  │ Donor HNA (neutrophil) antibodies             │
  │ → React with recipient neutrophils/leukocytes │
  │ → PMN activation → oxidative burst            │
  └──────────────────────────────────────────────┘
         OR
  ┌──────────────────────────────────────────────┐
  │ NON-IMMUNE MECHANISM (Type II - stored blood) │
  │ BRMs (Biological Response Modifiers) in       │
  │ stored plasma: lysophosphatidylcholines,       │
  │ CD40L → direct PMN activation                 │
  └──────────────────────────────────────────────┘
         ↓
  PMN degranulation + reactive oxygen species
         ↓
  Pulmonary capillary endothelial damage
         ↓
  ↑↑ Permeability → Protein-rich exudate → Pulmonary edema
         ↓
         TRALI

---

Clinical Features

---

Implicated Blood Products (High Plasma Volume)

1. Fresh Frozen Plasma (FFP) - highest risk
2. Apheresis platelets
3. Whole blood
4. Packed RBCs (lower risk)

---

Management

IMMEDIATE:
1. STOP transfusion immediately
2. Maintain IV access (saline keep-open)
3. Notify blood bank - report reaction + return bag
4. Save implicated unit + recipient sample for investigation

RESPIRATORY SUPPORT:
5. High-flow O₂
6. NIV (CPAP/BiPAP) for SpO₂ <94%
7. Intubation + mechanical ventilation if needed
   → Lung-protective strategy (as per ARDS protocol)
   → Low TV (6 mL/kg), PEEP, low plateau pressure

HEMODYNAMIC SUPPORT:
8. IV fluids carefully (NOT diuretics - unlike TACO)
9. Vasopressors if hypotension persists (noradrenaline)

INVESTIGATION:
10. ABG, CXR
11. Blood bank: HLA/HNA antibody testing (donor and recipient)
12. BNP, echo (exclude TACO)

NO ROLE FOR:
- Steroids (not proven beneficial)
- Diuretics (may worsen hypotension)

---

Prevention of TRALI

• Leukoreduction of blood products
• Male-only or nulliparous female FFP (reduces HLA antibody-containing donations)
• Limiting plasma from multiparous female donors
• Pathogen-reduced plasma
• Plasma-reduced platelet products
• ISBT definition screening of donors after TRALI report

• Goldman-Cecil Medicine - TRALI
• Murray & Nadel's Respiratory Medicine - Transfusion-Associated ALI
• Miller's Anesthesia, 10e - Table 45.8

---

QUESTION 7: Perioperative Uses of POCUS

Definition

Overview of Perioperative POCUS Applications

PERIOPERATIVE POCUS
        │
 ┌──────┴──────┬──────────────┬───────────────┐
PREOPERATIVE  INTRAOPERATIVE  POSTOPERATIVE   ICU/RECOVERY

---

1. Preoperative POCUS

Cardiac (Focused Cardiac Ultrasound - FoCUS)

• LV function: Assess LVEF (normal/impaired) - guides induction strategy
• RV function: Pulmonary hypertension, RV strain
• Pericardial effusion: Diagnose tamponade before induction
• Valvular disease: Severe aortic stenosis (AS), mitral regurgitation - alters anesthetic plan
• Fluid status: IVC diameter + collapsibility index (IVC CI):
  • IVC > 2 cm, non-collapsible → euvolemic/hypervolemic
  • IVC < 1.5 cm, > 50% collapse → hypovolemic

Gastric POCUS (Gastric Ultrasound)

• Gastric volume assessment: Empty stomach vs full stomach
• Identifies "at-risk" patients for aspiration
• Antrum visualization (right lateral decubitus):
  • Grade 0: Empty
  • Grade 1: Clear fluid <1.5 mL/kg
  • Grade 2: Solid content or clear fluid >1.5 mL/kg → RSI

Airway POCUS

• ETT confirmation: Tracheal vs esophageal intubation (lung sliding present = tracheal)
• Cricothyroid membrane identification (difficult airway)
• Subglottic diameter (pediatric tube size estimation)

Regional Anesthesia POCUS

• Vascular access assessment (antecubital fossa, neck veins)
• Nerve identification before blocks
• Spinal landmark identification (difficult neuraxial)

---

2. Intraoperative POCUS

Hemodynamic Monitoring

GOAL-DIRECTED THERAPY (GDT) using POCUS:
─────────────────────────────────────────
Hypotension during surgery → POCUS assessment:
  ↓ LV filling (small, hyperkinetic) → Hypovolemia → Fluid
  ↓ LV function (dilated, poor contractility) → Cardiogenic → Inotropes
  ↑ RV dilation → Obstructive (PE, pneumothorax) → Specific treatment
  Pericardial effusion → Tamponade → Pericardiocentesis
  Dynamic preload indicators (LVOT VTI, IVC variability under IPPV)

Lung POCUS (Intraoperative)

• Lung sliding: Confirms correct ETT placement (bilateral)
• B-lines: Pulmonary congestion/edema (intraoperative volume overload)
• Consolidation/Atelectasis: Guide lung recruitment
• Pneumothorax: A-lines + absent lung sliding + lung point
• Endobronchial intubation: Absent lung sliding on one side

Vascular Access (Intraoperative)

• Ultrasound-guided central line placement (subclavian, IJV, femoral)
• Arterial line (radial, brachial - in difficult access)
• Peripheral venous access (antecubital, basilic)

Nerve Blocks (Real-time guidance)

• Interscalene, supraclavicular, infraclavicular, axillary
• Femoral, popliteal sciatic, adductor canal
• TAP block, rectus sheath, erector spinae, serratus anterior
• Neuraxial (lumbar, thoracic, caudal)

---

3. Postoperative / Recovery POCUS

Acute Respiratory Failure

BLUE PROTOCOL (Bedside Lung Ultrasound in Emergency):
  A-profile (A-lines bilaterally) → Pneumothorax (if absent sliding) or
                                    Pulmonary embolism
  B-profile (B-lines bilaterally) → Pulmonary edema (cardiogenic or NCPE)
  A/B profile (asymmetric) → Pneumonia
  C-profile (consolidation) → Pneumonia/Atelectasis

Unexplained Hypotension

• FoCUS: Cardiac tamponade, LV failure, RV failure, hypovolemia
• Abdominal: Free fluid (hemoperitoneum), aortic dissection

DVT Assessment

• Compression ultrasound of lower limb veins

---

4. POCUS in Special Situations

---

POCUS Limitations

• Operator-dependent (requires training - WINFOCUS, ACEP, AIUM curricula)
• Cannot assess all structures (e.g., bone obstruction, BMI)
• Point-in-time snapshot, not continuous (unlike invasive monitoring)
• Poor acoustic window in some patients
• Mediastinal structures limited (TEE preferred intraoperatively for cardiac)
• Barash Clinical Anesthesia, 9e - Echocardiography and POCUS (Chapter 26)
• Miller's Anesthesia, 10e - Chapter 33: Perioperative Echocardiography and POCUS

---

QUESTION 8: Management of Hypoxia During One-Lung Ventilation (OLV)

Background

---

Pathophysiology of OLV Hypoxemia

TWO-LUNG VENTILATION → ONE-LUNG VENTILATION

Non-dependent (operative) lung:
  No ventilation → V/Q = 0 → TRUE SHUNT
  Blood flow continues to non-ventilated lung
  Deoxygenated blood returns to left atrium
  → ↓ PaO₂

Protective mechanism - HPV:
  HYPOXIC PULMONARY VASOCONSTRICTION (HPV)
  Low alveolar O₂ → Vasoconstriction in operative lung
  Diverts blood to ventilated lung
  REDUCES SHUNT by 50%
  (Reduces but does NOT eliminate shunt)

Factors INHIBITING HPV (worsen OLV hypoxemia):
  - Volatile anesthetics (dose-dependent) > 1 MAC
  - Vasodilators (nitroprusside, nitroglycerin)
  - Hypocapnia (↓ PaCO₂)
  - Alkalosis
  - Sepsis/SIRS

Factors POTENTIATING HPV (helpful):
  - TIVA (propofol) - preferred for OLV
  - Almitrine (IV - augments HPV)
  - Acidosis, hypercapnia (moderate)

---

Prevention Strategies (Before OLV Begins)

1. Pre-oxygenation: FiO₂ 1.0 for 3-5 min before lung collapse
2. Optimal double-lumen tube (DLT) position - fiberoptic confirmation
3. Identify high-risk patients (pre-existing contralateral lung disease, low preoperative SpO₂)
4. TIVA preferred over volatile agents (preserves HPV)
5. Position: Lateral decubitus - gravity assists HPV

---

Management Algorithm for OLV Hypoxemia

OLV HYPOXEMIA (SpO₂ < 90%)
         ↓
STEP 1: IMMEDIATE CHECKS
  ─ Check FiO₂ - increase to 1.0
  ─ Check DLT position (fiberoptic bronchoscope)
  ─ Check ventilated lung (secretions, pneumothorax, obstruction)
  ─ Check circuit disconnection or malfunction
         ↓
STEP 2: OPTIMIZE VENTILATION OF DEPENDENT (VENTILATED) LUNG
  ─ Tidal volume: 5-6 mL/kg (protective strategy)
  ─ RR: Adjust to PaCO₂ 40-45 mmHg
  ─ PEEP: 5-10 cmH₂O to dependent lung
  ─ Recruitment maneuvers to dependent lung
  ─ Suction secretions from ventilated lung
         ↓
STEP 3: APPLY CPAP TO OPERATIVE (NON-VENTILATED) LUNG
  ─ CPAP 2-5 cmH₂O with 100% O₂ to non-ventilated lung
  ─ Keeps alveoli open, allows O₂ diffusion
  ─ Most effective single intervention
  ─ Caution: Operative field inflation
         ↓
STEP 4: INTERMITTENT VENTILATION OF OPERATIVE LUNG
  ─ Request surgeon to pause periodically
  ─ Briefly reinflate and ventilate operative lung
  ─ Emergency measure
         ↓
STEP 5: PHARMACOLOGICAL
  ─ Almitrine (1 mcg/kg/min IV) - augments HPV in operative lung
  ─ Inhaled NO or nebulized prostacyclin (dilate vessels in ventilated lung)
  ─ Adjust anesthetic: Switch to TIVA (propofol) if on volatile
         ↓
STEP 6: SURGICAL INTERVENTION
  ─ Request ligation of pulmonary artery to operative lobe/lung
  ─ Eliminates shunt through that lung (most effective)
         ↓
STEP 7: ABANDON OLV
  ─ Convert to two-lung ventilation
  ─ Reposition DLT/use bronchial blocker for partial isolation
  ─ Notify surgeon - modify surgical approach if possible
         ↓
STEP 8: LAST RESORT
  ─ ECMO (extracorporeal membrane oxygenation) for refractory cases
  ─ Rare - only in extreme cases (bilateral lung disease)

---

DLT vs Bronchial Blocker

---

OLV Ventilation Strategy (Lung Protective)

• Miller's Anesthesia, 10e - Hypoxemia during OLV

---

QUESTION 9: Informed Consent - Ethics & Documentation

Definition

---

Ethical Foundations

Four Principles of Biomedical Ethics (Beauchamp & Childress)

1. AUTONOMY
   "Respect for patient's right to decide"
   → Informed consent operationalizes autonomy
   → Patients can accept OR refuse treatment
   → Includes right to withdraw consent

2. BENEFICENCE
   "Act in the patient's best interest"
   → Provide treatment that benefits the patient
   → Tension with autonomy when patient refuses beneficial treatment

3. NON-MALEFICENCE
   "First, do no harm" (Primum non nocere)
   → Risks must be proportionate to benefits
   → All anesthetic risks must be disclosed

4. JUSTICE
   "Fair distribution of benefits and burdens"
   → Equal access to care
   → Non-discrimination in consent process

---

Elements of Valid Informed Consent

VALID CONSENT = CAPACITY + INFORMATION + VOLUNTARINESS

1. CAPACITY (Competence):
   ─ Patient can understand the information
   ─ Patient can retain the information
   ─ Patient can weigh options
   ─ Patient can communicate a decision
   (All four - "URWC" model, Mental Capacity Act framework)

   LACK OF CAPACITY:
   ─ < 18 years (minor) → Parent/guardian consent
     (Gillick competence: mature minor may consent for themselves)
   ─ Unconscious → Emergency treatment under implied consent / best interest
   ─ Mental illness → Not automatic incapacity; assess each case
   ─ Intellectual disability → Assess individually

2. INFORMATION (Disclosure standard):
   ─ Diagnosis and proposed treatment
   ─ Benefits of treatment
   ─ Material risks (those a reasonable patient in their situation would want to know)
   ─ Alternatives (including no treatment)
   ─ Likely outcome with and without treatment
   ─ Opportunity to ask questions

   MONTGOMERY STANDARD (UK Law, 2015):
   Replaced "Bolam test" for consent
   Must disclose risks that a "reasonable patient" would consider significant
   NOT what a "reasonable doctor" would disclose
   → Patient-centered disclosure model

   Indian Context (Consumer Protection Act, 1986 / Samira Kohli case 2008):
   ─ Consent must be specific to the procedure
   ─ Real consent vs formal consent
   ─ Must explain nature, consequences, and alternatives

3. VOLUNTARINESS:
   ─ Free from coercion, undue influence, or manipulation
   ─ Patient can change mind at any time

---

Specific Anesthetic Consent Issues

What Must Be Disclosed for Anesthesia

• Type of anesthesia planned and why
• Alternative anesthetic techniques
• Common risks (>1%): PONV, sore throat, dental damage, awareness, headache (if spinal)
• Serious rare risks (<1% but serious): anaphylaxis, nerve damage, awareness, death (must disclose if asked)
• Specific risks based on patient factors (OSA → difficult airway, obesity → aspiration)
• Plan for postoperative analgesia

Pre-anesthetic Consent - Specific Points

• Awareness under general anesthesia: Must be mentioned (1:19,000 cases)
• Regional anesthesia: Failure rates, nerve injury, LAST
• Blood transfusion: Must be mentioned separately (Jehovah's Witness - advance directive)
• Blood pressure changes during surgery: General information
• Emergency situations: Anesthesiologist has duty of care; consent for additional procedures if life-threatening emergency arises

---

Documentation of Consent

What Must Be Documented (Consent Form)

ANESTHESIA CONSENT FORM COMPONENTS:
──────────────────────────────────────
Patient identification (name, DOB, MRN)
Proposed procedure and anesthetic technique
Statement that information was provided and understood
Risks discussed (list significant ones)
Alternatives discussed
Patient's questions and answers
Date, time, patient signature
Witness signature
Anesthesiologist's signature and designation
Language of communication (interpreter if needed)
Capacity assessment documented if any concern

Types of Consent

---

Special Situations

Emergency Consent

• Life-threatening emergency → Treatment can proceed without consent
• Document: "Emergency treatment provided in patient's best interest"
• Attempt to contact NOK (next of kin)

Refusal of Treatment

• Competent adult has absolute right to refuse ANY treatment
• Even if refusal leads to death (e.g., Jehovah's Witness refusing blood)
• Document refusal thoroughly; obtain written refusal if possible
• Seek legal opinion if doubt about capacity

Minors

• Age <18 in India/UK: Parent/guardian signs
• Gillick competence/Fraser guidelines (UK): Mature minor can consent if they understand
• Age <7: Assent (not consent) appropriate; involves child in discussion

Jehovah's Witnesses

• Inform blood bank - no transfusion
• Document: Cell saver acceptable/not? IV immunoglobulin? Albumin?
• Have detailed discussion and specific consent form
• Court order for minors if life-threatening

---

Flowchart: Consent Process in Anesthesia

Patient referred for surgery
         ↓
Pre-anesthetic assessment
         ↓
Assess CAPACITY
    ↓         ↓
Has capacity   Lacks capacity
    ↓              ↓
Provide       Best interest decision
information   (family/ethics/court)
    ↓
Explain: Procedure, technique,
risks, alternatives, benefits
    ↓
Address questions
    ↓
Patient VOLUNTARILY agrees
    ↓
DOCUMENT: Sign consent form
Date, witness, countersign
    ↓
Opportunity to withdraw
consent at any time
    ↓
Day of surgery: RE-CONFIRM consent
(patient may have changed mind)

• Miller's Anesthesia, 10e - Medical Ethics Principles, Autonomy
• Schwartz's Principles of Surgery, 11e - Informed Consent

---

QUESTION 10A: Uterus - Diagram, Blood Supply & Nerve Supply

Anatomy of the Uterus

Structure

• Length: 7.5 cm
• Width (fundus): 5 cm
• Thickness: 2.5 cm
• Weight: 30-40 g

                    ┌─────────────────────┐
                    │       FUNDUS        │
           Fallopian│    (dome-shaped     │Fallopian
             tube ──│──→ top of uterus) ←─│── tube
                    │                     │
                    │       BODY          │
                    │    (corpus - main   │
          Ovary ────│──→     part)        │──── Ovary
                    │                     │
                    │  ISTHMUS            │
                    │  (constricted part, │
                    │  3 cm above cervix) │
                    │                     │
                    │       CERVIX        │
                    │  ┌───────────────┐  │
                    │  │ Internal os   │  │
                    │  │ Cervical canal│  │
                    │  │ External os   │  │
                    └──┴───────────────┴──┘
                              ↓
                            VAGINA

• Perimetrium (outer serous peritoneal coat)
• Myometrium (middle thick muscular layer - 3 sublayers)
• Endometrium (inner mucous membrane - functional + basal layers)

Relations

• Anterior: Bladder (vesicouterine pouch of peritoneum)
• Posterior: Rectum (rectouterine pouch / Pouch of Douglas)
• Lateral: Broad ligament, uterine tubes, ovaries
• Inferior: Vagina

Ligaments of Uterus

---

Blood Supply of Uterus

Arterial Supply

AORTA
  ↓
Internal Iliac Artery (Hypogastric)
  ↓
Anterior Division
  ↓
UTERINE ARTERY
  ↓ (crosses ureter "water under bridge" - 2 cm lateral to cervix)
Ascends along lateral uterine wall
  ├── Fundal branch
  ├── Tubal branch (to tube)
  ├── Ovarian branch (anastomoses with ovarian artery)
  └── Cervical/Vaginal branches

ANASTOMOSIS:
  Uterine artery ↔ Ovarian artery (from aorta)
  (Creates dual blood supply - important in obstetric hemorrhage)

COLLATERAL:
  Ovarian artery ← Abdominal aorta (directly, L2 level)

Venous Drainage

• Uterine veins → Internal iliac vein → Iliac vein → Inferior vena cava
• Uterine plexus (broad ligament) connects with ovarian, vaginal, vesical plexuses

Lymphatic Drainage

---

Nerve Supply of Uterus

SYMPATHETIC:                    PARASYMPATHETIC:
T10 - L2                       S2, S3, S4
  ↓                              ↓
Pre-aortic plexus          Pelvic splanchnic nerves
  ↓                              ↓
Hypogastric plexus ←────── Pelvic plexus (inferior hypogastric)
  ↓                              ↓
Uterine nerves             Cervicovaginal ganglia
                                 ↓
                    FRANKENHÄUSER'S (PARACERVICAL) GANGLION
                    (at junction of uterus and vagina, laterally)

PAIN TRANSMISSION:
  Body of uterus (visceral pain):   T10-L1 → Sympathetic
  Cervix/vagina (local pain):       S2-S4 → Parasympathetic + Somatic
  Perineum:                         Pudendal nerve (S2-S4)

• Epidural/spinal must cover T10 for uterine body pain (labor 1st stage)
• Pudendal block covers 2nd stage perineal pain
• Paracervical block (Frankenhäuser's ganglion) blocks uterine/cervical pain
• Level of spinal for cesarean section: T4-T6 (to cover peritoneal traction)

---

QUESTION 10B: Physiological and Anatomical Changes in Pregnancy

Overview

• hCG (early)
• Progesterone (smooth muscle relaxation throughout)
• Estrogen (fluid, vascular changes)
• Mechanical effects of growing uterus
• Placental hormones (HPL, relaxin)

---

1. Respiratory System

• Rapid desaturation with apnea (↓ FRC + ↑ O₂ consumption) - pre-oxygenate well before induction
• Lower MAC for volatile agents (progesterone effect)
• Airway edema: Difficult intubation, use smaller ETT (6.0-6.5 mm)
• Mucosal engorgement: Avoid nasal intubation (bleeding risk)

---

2. Cardiovascular System

> 20 weeks gestation:
Uterus compresses IVC (and to lesser extent aorta) in supine position
→ ↓ Venous return → ↓ Preload → ↓ CO → ↓ Placental perfusion
→ SUPINE HYPOTENSION SYNDROME (10-15% of pregnancies)

PREVENTION:
  Left lateral tilt ≥15° (wedge under right hip)
  Manual uterine displacement (LUD)

---

3. Gastrointestinal System

• ALL pregnant women >18-20 weeks are considered FULL STOMACH
• Mandatory RSI (Rapid Sequence Induction) for GA
• Pre-medicate: sodium citrate (30 mL oral) + ranitidine + metoclopramide
• Cricoid pressure during laryngoscopy

---

4. Renal System

---

5. Hematological System

---

6. CNS / Neurological

---

7. Musculoskeletal / Anatomical Changes

• Lumbar lordosis increases (shifted center of gravity)
• Sacroiliac joint laxity (relaxin)
• Symphysis pubis separation
• Diaphragm elevated 4 cm (by growing uterus)

---

Summary Table: Key Changes for Anesthesia Practice

SYSTEM      CHANGE              ANESTHETIC IMPLICATION
─────────────────────────────────────────────────────────────────────
Airway      Edema, mucosal      Smaller ETT (6.0-6.5)
            engorgement         No nasal airway; difficult intubation

Respiratory ↓ FRC               Pre-oxygenate well (4 min 100% O₂)
            ↑ O₂ consumption    RSI without waiting for Hb desaturation
            ↑ MV                ↓ MAC - reduce volatile dose

CVS         ↑ CO, ↓ SVR         Higher cardiac output → faster IV drug effect
            Aortocaval compress  LUD (15° left lateral tilt) when >20 wks

GIT         Full stomach         RSI mandatory for GA ≥18 wks
            ↓ LES tone           Antacid premedication

CNS         ↓ MAC               Reduce volatile by ~25-40%
            ↓ LA requirement    Reduce epidural/spinal LA dose by ~30%
            Engorged epi veins  Higher IV catheter placement risk

Coagulation Hypercoagulable     DVT prophylaxis; check platelets pre-neuraxial

• Morgan & Mikhail's Clinical Anesthesiology, 7e - Physiological Changes of Pregnancy

---

Quick Index

---

FAT June 2026 - Second Paper: Comprehensive DNB Answers

---

QUESTION 1: 45-Year-Old Male, CKD on Maintenance Hemodialysis - Elective Laparoscopic Cholecystectomy

Introduction

---

Preoperative Assessment

History

• Duration of CKD, cause (diabetic nephropathy, hypertensive, GN)
• Hemodialysis schedule - when was last dialysis? (aim for surgery 4-6 hr after last session - optimal fluid/electrolyte status)
• Residual urine output (anuric vs. oliguric)
• Comorbidities: Hypertension (present in >80%), diabetes, ischemic heart disease, anemia, peripheral vascular disease
• Current medications: Antihypertensives (ACE-I/ARB - hold morning of surgery), erythropoietin, phosphate binders, immunosuppressants (if transplant)
• Vascular access site: AV fistula location (upper limb) - PROTECT at all costs

Examination

• BP both arms (avoid fistula arm)
• Signs of fluid overload (bilateral crackles, JVP, peripheral edema)
• Signs of uremic encephalopathy
• Airway, vascular access
• AV fistula: thrill/bruit present? (patency)

Investigations

Timing of Surgery Relative to Dialysis

OPTIMAL: Surgery 4-6 hours AFTER dialysis session
  → K⁺ normalized
  → Fluid balance optimized (not immediately post-dialysis - hypotensive)
  → Acid-base normalized

AVOID:
  → Surgery > 24 hr after last dialysis (K⁺ rises ~0.5 mEq/L/hr in anuric patient)
  → Immediate post-dialysis (hemodynamic instability)

---

Specific CKD-Related Anesthetic Problems

1. Hyperkalemia - Most Critical Concern

K⁺ rises with:
  → Each hour after dialysis (especially anuric patient)
  → Acidosis (H⁺ shifts out, K⁺ shifts in)
  → Succinylcholine (↑ K⁺ by 0.5-1.0 mEq/L - AVOID if K⁺ >5.0 mEq/L)
  → Tissue necrosis / hemolysis / blood transfusion
  → Metabolic acidosis during surgery

HYPERKALEMIA ECG CHANGES:
  K⁺ 5.5-6.5: Peaked T waves
  K⁺ 6.5-7.0: ↑ PR interval, ↓ P amplitude
  K⁺ >7.0:   Widened QRS, sine-wave pattern → VF/Asystole

TREATMENT OF INTRAOPERATIVE HYPERKALEMIA:
  1. Calcium gluconate 10 mL of 10% IV (membrane stabilization - immediate)
  2. NaHCO₃ 50 mEq IV (shifts K⁺ into cells)
  3. Insulin 10 U + Dextrose 50 g IV (shifts K⁺ into cells - 30-60 min)
  4. Salbutamol nebulization / IV (shifts K⁺ into cells)
  5. Furosemide (if any residual renal function)
  6. Kayexalate (resonium - delayed effect, post-op)
  7. Emergency hemodialysis post-operatively
  8. Avoid succinylcholine

2. Anemia

• Usually normochromic normocytic (EPO deficiency)
• Hb 8-10 g/dL typical - well tolerated by dialysis patients (chronic adaptation)
• Minimum Hb 8 g/dL for elective surgery (some centers accept 7 in adapted patients)
• Preop EPO dose can be increased 2-3 weeks before surgery
• Transfuse if Hb < 7 g/dL or hemodynamically compromised
• Use blood cautiously (K⁺ load in stored blood, immunosensitization pre-transplant)

3. Uremic Platelet Dysfunction

• Platelet count may be normal, BT prolonged
• Due to: Uremic toxins impairing GPIb-IIb/IIIa function
• Treatment pre-op:
  • Desmopressin (DDAVP) 0.3 mcg/kg IV (releases vWF - improves platelet adhesion, onset 1 hr, duration 4-8 hr)
  • Cryoprecipitate (contains vWF, fibronectin)
  • Conjugated estrogens 0.6 mg/kg/day x 5 days (long-lasting)
  • Dialysis itself improves platelet function

4. Cardiovascular Disease

• #1 cause of mortality in ESRD patients
• LVH, diastolic dysfunction, coronary artery disease
• Hypertension (often difficult to control)
• Pericardial effusion (uremic pericarditis)
• Pulmonary hypertension (chronic fluid overload + pulmonary vasoconstriction)
• Risk: Cardiac arrhythmias during pneumoperitoneum (vagal + hyperkalemia)

5. Drug Metabolism & Pharmacokinetics in CKD

AVOID / USE WITH CAUTION:
───────────────────────────────────────────────────────────
Drug               Reason to Avoid/Modify
───────────────────────────────────────────────────────────
Succinylcholine    ↑ K⁺ (0.5-1 mEq/L), avoid if K⁺ >5.0
Morphine           Active metabolite M6G accumulates → prolonged respiratory depression
Meperidine         Normeperidine accumulation → seizures
NSAIDs             Residual renal function loss; platelet dysfunction
Metoclopramide     Dose reduce (renally cleared)
Neostigmine        Prolonged effect (renally cleared) - use with caution
Gallamine          Entirely renal excretion - avoid
Pancuronium        70% renal excretion - avoid or reduce dose

SAFE/PREFERRED:
───────────────────────────────────────────────────────────
Atracurium         Hofmann elimination + ester hydrolysis - PREFERRED
Cisatracurium      Same - PREFERRED (less laudanosine)
Fentanyl           Hepatic metabolism, inactive metabolites - SAFE
Sufentanil         Safe
Remifentanil       Plasma esterases - IDEAL for CKD
Propofol           Hepatic - SAFE
Sevoflurane        Compound A concern in low-flow - use >2 L/min fresh gas
Isoflurane         SAFE
Vecuronium         25% renal (rest biliary) - use cautiously
Rocuronium         Primary biliary (10-25% renal) - dose reduction needed
Sugammadex         Renally excreted complex - use full dose but may need prolonged monitoring
Paracetamol        SAFE (dose reduction in severe CKD not usually needed)

---

Laparoscopic Considerations in CKD

PNEUMOPERITONEUM EFFECTS (exaggerated in CKD):
──────────────────────────────────────────────────────
↑ IAP → ↓ Renal blood flow (already zero in ESRD - less critical)
       → ↓ Cardiac output → Hypotension
       → ↑ ETCO₂ (absorption) → Acidosis → ↑ K⁺ (worsens hyperkalemia)
       → ↑ SVR

MANAGEMENT:
  → Low insufflation pressure (10-12 mmHg, not 15 mmHg standard)
  → Neutral or mild Trendelenburg (not steep)
  → Monitor K⁺ and pH with serial ABGs
  → ↑ RR to maintain normocapnia (prevent acidosis-driven hyperkalemia)

---

Anesthetic Plan

Preoperative

1. Optimize dialysis - day before surgery (or morning of for AM surgery)
2. Target K⁺ < 5.5, HCO₃ > 18
3. DDAVP 0.3 mcg/kg 1 hour before if bleeding expected
4. Hold ACE-I/ARB morning of surgery (severe intraoperative hypotension risk)
5. Continue antihypertensives otherwise
6. IV access: Avoid fistula arm entirely (no BP cuff, no IV, no ABG)

Induction

• Preoxygenation (FRC often reduced in fluid-overloaded CKD patient)
• RSI if fluid-overloaded (gastroparesis in diabetic CKD, aspiration risk)
• Propofol or Thiopentone for induction (reduce dose - protein binding ↓ in CKD → free fraction ↑)
• Rocuronium (preferred for RSI, given lack of succinylcholine) - dose 1.2 mg/kg
• Reverse with Sugammadex (preferred over neostigmine; neostigmine renally cleared)
• If succinylcholine needed (truly difficult airway + aspiration risk): Verify K⁺ < 5.0 first

Maintenance

• Volatile agent: Isoflurane/desflurane preferred (minimal renal metabolism)
  • Sevoflurane: Compound A with CO₂ absorbers - use fresh gas flow >2 L/min
• Muscle relaxant: Atracurium or cisatracurium (Hofmann elimination - unaffected by renal failure)
• Opioid: Fentanyl (short-term) or Remifentanil infusion (ideal - plasma esterases)
• Avoid morphine (active M6G metabolite accumulates → prolonged sedation + respiratory depression)

Monitoring

• Standard ASA + invasive arterial line (beat-to-beat BP, serial ABGs)
• Avoid fistula arm for all monitoring
• Urine output monitoring: Not useful (anuric patient)
• Serial K⁺, pH, glucose (ABG machine)
• Temperature (hypothermia → acidosis → ↑ K⁺)

Fluid Management

• Restrict crystalloids (no renal excretion of excess fluid)
• No Hartmann's/Ringer's lactate (contains K⁺ 4-5 mEq/L) - use 0.9% saline or Plasmalyte
• Monitor for fluid overload: POCUS (IVC diameter, lung B-lines)
• Vasopressors (phenylephrine/norepinephrine) for hypotension rather than fluid

Postoperative

KEY POST-OP CONSIDERATIONS:
────────────────────────────────────────────────────────
1. K⁺ monitoring: Serial K⁺ every 4-6 hr post-op
2. Analgesia:
   - Paracetamol: Safe (preferred)
   - NSAIDs: AVOID (worsening residual renal function + platelet dysfunction)
   - Tramadol: Reduce dose (active metabolite accumulation)
   - Fentanyl PCA: Appropriate (hepatic metabolism)
3. Dialysis: Plan post-op HD if:
   - Hyperkalemia develops
   - Fluid overload
   - Metabolic acidosis worsening
4. Wound: Monitor for hematoma (uremic platelet dysfunction)
5. Resume dialysis schedule day 1 post-op (if no hemodynamic issues)
6. DVT prophylaxis: Heparin dose adjust (use anti-Xa monitoring)
7. Antiemetics: Ondansetron (safe); avoid metoclopramide or dose-reduce

---

Flowchart: Anesthetic Management

Preoperative
  → Last HD: 4-6 hr before surgery
  → K⁺ < 5.5, HCO₃ > 18, Hb > 10
  → DDAVP if BT prolonged
  → ECG (hyperkalemia changes?)
       ↓
Induction
  → Protect AV fistula (NO BP/IV/ABG on fistula arm)
  → RSI: Propofol + Rocuronium 1.2 mg/kg (no succinylcholine if K⁺ >5)
  → Art line pre-induction
       ↓
Maintenance
  → Isoflurane / Desflurane in O₂/Air
  → Atracurium / Cisatracurium (NMB top-ups)
  → Remifentanil infusion / Fentanyl boluses
  → Serial ABGs: Monitor K⁺, pH, glucose
  → Pneumoperitoneum: Low pressure (10-12 mmHg), ↑ RR for normocapnia
  → Restrictive fluids (0.9% NaCl only) + vasopressors for BP
       ↓
Emergence
  → Sugammadex reversal (preferred)
  → Awake extubation
  → Watch for laryngospasm (hypocalcemia)
       ↓
Postoperative
  → K⁺ monitoring q 4-6 hr
  → Paracetamol analgesia (no NSAIDs)
  → Resume dialysis Day 1 post-op
  → Watch for fluid overload, delayed awakening (drug accumulation)

---

QUESTION 2: Uptake & Distribution of Inhalational Agents & TEC 6 Vaporizer

A. Uptake and Distribution of Inhalational Agents

---

Key Concept: FA/FI Ratio

GOAL OF ANESTHESIA: FA/FI → 1.0 (alveolar concentration approaches inspired)
  → Faster this ratio rises = faster induction
  → Brain equilibrates with blood, blood equilibrates with alveoli

Agents with LOW blood:gas solubility → FA/FI rises RAPIDLY → Fast induction
  (Desflurane, N₂O)
Agents with HIGH blood:gas solubility → FA/FI rises SLOWLY → Slow induction
  (Halothane, Diethyl ether)

---

Blood:Gas Partition Coefficient (Ostwald Coefficient) - Most Important Property

---

Factors Affecting FA/FI Rise (Uptake)

FA/FI RISES FASTER WITH:               FA/FI RISES SLOWER WITH:
─────────────────────────────────────────────────────────────────
↑ Alveolar ventilation                  ↓ Alveolar ventilation (↑ FRC)
↓ Blood:gas solubility                  ↑ Blood:gas solubility
↓ Cardiac output                        ↑ Cardiac output
↓ Alveolar-venous partial press diff    ↑ Cardiac output (washes away alveolar agent)
Second gas effect (N₂O)
Concentration effect (high FI)

---

Steps in Uptake and Distribution

STEP 1: DELIVERY TO ALVEOLUS
  Machine → Circuit → Airway → Alveolus
  Governed by: Fresh gas flow, vaporizer setting, dead space, FRC

STEP 2: UPTAKE FROM ALVEOLUS TO BLOOD
  Q = (FA - Fv) × λb/g × Q̇
  Where: λb/g = blood:gas partition coefficient
         Q̇ = cardiac output
         Fv = mixed venous partial pressure

  HIGH cardiac output → More agent removed from alveolus → FA/FI rises SLOWER
  (Contrast: IV drugs - high CO = faster distribution = FASTER induction)

STEP 3: DISTRIBUTION FROM BLOOD TO TISSUES
  Tissue groups by perfusion:
  ┌─────────────────────────────────────────────────────────────┐
  │ VESSEL-RICH GROUP (VRG): Brain, heart, liver, kidney (10%)  │
  │ → High perfusion → Equilibrates in MINUTES                  │
  │ → Most relevant for anesthetic depth                        │
  ├─────────────────────────────────────────────────────────────┤
  │ MUSCLE GROUP (MG): Skeletal muscle (50% body mass)          │
  │ → Moderate perfusion → Equilibrates in 30-90 min            │
  │ → Important for prolonged cases                              │
  ├─────────────────────────────────────────────────────────────┤
  │ FAT GROUP: Adipose tissue (20% body mass)                   │
  │ → Low perfusion, high capacity → Equilibrates in hours/days │
  │ → Major factor in prolonged anesthesia + obese patients     │
  └─────────────────────────────────────────────────────────────┘

STEP 4: BRAIN EQUILIBRATION
  Brain equilibrates with blood
  Brain:Blood partition coefficient (~1.4-2.0 for most agents)
  Anesthetic depth correlates with brain partial pressure

---

Special Effects

• High inspired concentration (e.g., 70% N₂O) → Rapid absorption → "Concentrating" of remaining gases → FA rises faster than expected

• When N₂O is absorbed rapidly, it creates a slight negative pressure
• This concentrates co-administered volatile agent (e.g., sevoflurane)
• FA of second gas rises faster than expected

On discontinuing N₂O:
  N₂O rapidly exits blood → Alveolus flooded with N₂O
  Dilutes alveolar O₂ → ↓ PAO₂ → HYPOXIA
  
PREVENTION: Administer 100% O₂ for 5-10 min at end of N₂O anesthesia

---

Recovery from Inhalational Anesthesia

• Fat depot release: High-solubility agents stored in fat, released slowly
• Context-sensitive recovery: Longer anesthesia → more tissue accumulation → slower emergence
• Desflurane fastest recovery (low blood:gas + low tissue solubility)
• Sevoflurane rapid recovery
• Halothane slow recovery (high solubility in all tissues)

---

B. TEC 6 Vaporizer (Desflurane-Specific)

Why Desflurane Needs a Specialized Vaporizer

Desflurane Properties:
  Boiling point: 22.8°C (near room temperature!)
  At 20°C room temperature → Desflurane BOILS → Unpredictable vapor output
  SVP at 20°C: 669 mmHg (vs sevoflurane: 159 mmHg)
  
If used in standard vaporizer:
  → Uncontrolled vaporization
  → Unpredictable, potentially lethal concentrations delivered

TEC 6 Vaporizer Design

ELECTRICALLY HEATED & PRESSURIZED SYSTEM
──────────────────────────────────────────────────────

KEY FEATURES:
  1. HEATED SUMP (pressurized):
     - Desflurane heated to 39°C (ensures constant boiling)
     - Sump pressurized to 1.5 atm (1550 mmHg)
     - Desflurane exists as pure vapor (not liquid) in sump
     
  2. ELECTRONIC CONTROL:
     - Dial-controlled differential pressure transducer
     - Vapor flow regulated by electronic valve
     - Not a variable bypass system - INJECTOR system
     
  3. TWO SEPARATE GAS STREAMS:
     Stream 1: Fresh gas flow (from machine) - bypasses sump
     Stream 2: Pure desflurane vapor (from pressurized sump)
     → Both streams merge at output
     → Concentration of desflurane determined by ratio
     
  4. TEMPERATURE COMPENSATION:
     - Thermostatically maintained sump at 39°C
     - Output independent of ambient temperature (unlike conventional vaporizers)
     
  5. ALARM SYSTEM:
     - Low agent alarm (< 20 mL)
     - Power failure alarm (cannot function without electricity)
     - Temperature alarm

DIAGRAM:

  FRESH GAS FLOW
  ────────────────────────────────────────→ OUTPUT
                              ↑ (electronic valve)
  Pressurized heated sump    │
  [Desflurane @ 39°C, 1.5 atm]
  → Pure desflurane vapor injected into FGF

Safety Features of TEC 6

• Must be upright during operation (filling)
• Interlock mechanism: Cannot be filled while in use
• Colour-coded (blue - for desflurane)
• Keyed filling device (cannot fill wrong agent)
• Automatically warms up on start (takes ~5-10 min)
• Will not function below certain temperature

Comparison: TEC 6 vs Standard Variable Bypass Vaporizer

---

QUESTION 3: Causes of Perioperative Arrhythmias & Management of Ventricular Arrhythmias

A. Causes of Perioperative Arrhythmias

Classification by Mechanism

PERIOPERATIVE ARRHYTHMIAS
         │
    ┌────┴────────────┐
PATIENT FACTORS   SURGICAL FACTORS   ANESTHETIC FACTORS
    │                  │                     │
Pre-existing    Surgical stimulus      Drug effects
cardiac disease Peritoneal traction     Airway manipulation
Electrolytes    Direct cardiac manip   Hypoxia/hypercapnia
                                       Equipment

Detailed Causes

• Pre-existing cardiac disease (IHD, heart failure, cardiomyopathy)
• Hypo/hyperkalemia, hypomagnesemia, hypocalcemia
• Hypo/hyperthyroidism
• Hypoxia (most common intraoperative cause)
• Hypercapnia (sympathetic activation → arrhythmias)
• Acid-base disturbances
• Hypothermia (Q-T prolongation → VF at < 28°C)
• Pheochromocytoma (catecholamine excess)

• Laryngoscopy and intubation: Sympathetic surge → Sinus tachycardia, SVT, VT
• Extubation: Sinus tachycardia, hypertension
• Peritoneal/mesenteric traction: Vagal → Bradycardia, heart block
• Laparoscopy: Vagal (bradycardia) + hypercapnia (VT) + ↑ IAP
• Eye surgery: Oculocardiac reflex (VV → Bradycardia, V-block, asystole)
• Cardiac surgery: Direct manipulation, cardioplegia, reperfusion
• Carotid endarterectomy: Sinus node artery manipulation
• Head and neck surgery: Carotid sinus stimulation

• Hypoxia and Hypercarbia: Most common, must always be excluded first
• Volatiles: Sensitize myocardium to catecholamines (halothane >> sevoflurane > desflurane)
• Halothane: Most arrhythmogenic (Q-T prolongation + sensitization to adrenaline)
• Succinylcholine: Bradycardia (M2 receptor activation), junctional rhythms, VF
• Anticholinesterases: Bradycardia if insufficient anticholinergic
• Induction agents: Propofol (bradycardia, blocks IKr → Q-T changes), ketamine (tachycardia)
• Central line placement: Catheter tip in right heart → VPCs, VT
• Electrolyte administration errors
• Air/gas embolism: Bradycardia, VF

---

B. Management of Ventricular Arrhythmias

Classification of Ventricular Arrhythmias

VENTRICULAR ARRHYTHMIAS
         │
  ┌──────┴──────────┐
BENIGN              MALIGNANT
  │                    │
Isolated VPCs      Ventricular Tachycardia (VT)
Bigeminy           Ventricular Fibrillation (VF)
Trigeminy          Pulseless VT
                   Polymorphic VT (Torsades de Pointes)

---

Ventricular Premature Contractions (VPCs)

• Wide QRS (>0.12s), no preceding P wave
• Benign VPCs (intraoperative): Usually require no treatment - address cause
• Treat if:

  • 6 VPCs/min

  • R-on-T phenomenon (VPC on T wave of preceding beat - can trigger VF)
  • Runs of VPCs (3 = non-sustained VT)
  • Multifocal VPCs
  • New onset in hemodynamically compromised patient

1. Identify and treat reversible cause (hypoxia, hypercarbia, hypokalemia, light anesthesia)
2. Lidocaine 1-1.5 mg/kg IV if persistent
3. Correct electrolytes

---

Sustained Monomorphic VT (with pulse)

IMMEDIATE ASSESSMENT:
  ↓
Is patient HEMODYNAMICALLY STABLE?
  ↓ YES                    ↓ NO (↓ BP, ↓ consciousness)
  ↓                         ↓
PHARMACOLOGICAL         SYNCHRONIZED DC CARDIOVERSION
   Management                (100 J biphasic)
  ↓                            ↓
FIRST LINE:              After cardioversion:
  Amiodarone              Amiodarone 150 mg IV over 10 min
  150 mg IV over 10 min       then infusion 1 mg/min x 6 hr
  Then 1 mg/min infusion      then 0.5 mg/min
  Max 2.2 g/24 hr
  ↓
SECOND LINE:
  Lidocaine 1-1.5 mg/kg IV
  Then 1-4 mg/min infusion
  ↓
THIRD LINE:
  Procainamide 20-50 mg/min (not widely available)
  Sotalol IV (if K⁺ and QTc normal)

---

Pulseless VT / Ventricular Fibrillation (VF)

IMMEDIATE CARDIAC ARREST PROTOCOL (ACLS 2020):

CONFIRM: Pulseless VT / VF → SHOCKABLE RHYTHM

1. HIGH QUALITY CPR
   → Rate: 100-120/min
   → Depth: ≥5 cm (2 inches)
   → Full chest recoil
   → Minimize interruptions
   → 30:2 ratio if no advanced airway

2. DEFIBRILLATION (as soon as available)
   → Biphasic: 120-200 J (manufacturer recommendation)
   → Monophasic: 360 J
   → Resume CPR IMMEDIATELY after shock

3. AIRWAY MANAGEMENT
   → Intubation (if available) → ETT
   → Continuous compressions (no pause for ventilation)

4. IV/IO ACCESS
   → Peripheral IV or IO (if no IV)

5. EPINEPHRINE (ADRENALINE)
   → 1 mg IV/IO every 3-5 min
   → Give ASAP for non-shockable (PEA/asystole)
   → After 1st or 2nd shock for shockable rhythm

6. AMIODARONE (for shock-refractory VF/VT)
   → 300 mg IV/IO bolus (1st dose)
   → 150 mg IV/IO bolus (2nd dose)
   
   OR LIDOCAINE (alternative if amiodarone unavailable):
   → 1-1.5 mg/kg IV/IO (1st dose)
   → 0.5-0.75 mg/kg (2nd dose)

7. TREAT REVERSIBLE CAUSES (H's and T's):
   ┌─────────────────┬───────────────────┐
   │ H's             │ T's               │
   ├─────────────────┼───────────────────┤
   │ Hypoxia         │ Tension pneumothorax│
   │ Hypovolemia     │ Tamponade         │
   │ Hydrogen ion (acidosis)│ Toxins     │
   │ Hypo/Hyperkalemia│ Thrombosis (PE)  │
   │ Hypothermia     │ Thrombosis (MI)   │
   └─────────────────┴───────────────────┘

8. CPR CYCLE: 2 minutes CPR → Check rhythm → Shock if shockable → Repeat

---

Torsades de Pointes (TdP) - Polymorphic VT with Long QT

RECOGNITION:
  Polymorphic VT with varying QRS axis
  "Twisting of the points" around isoelectric baseline
  Associated with LONG QT interval (>450 ms men, >470 ms women)

CAUSES IN PERIOPERATIVE SETTING:
  Drug-induced: Halothane, ondansetron, amiodarone, droperidol, ketamine
  Electrolytes: Hypokalemia, Hypomagnesemia
  Congenital Long QT (Romano-Ward, Jervell-Lange-Nielsen)
  Bradycardia
  Hypothermia

MANAGEMENT OF TdP:
  1. DC cardioversion / defibrillation if hemodynamically unstable
  2. MAGNESIUM SULFATE 2g IV over 5-10 min (FIRST LINE for drug-induced TdP)
     → Even if Mg²⁺ is normal
  3. Correct K⁺ (target K⁺ > 4.5 mEq/L in TdP)
  4. Overdrive pacing (increase HR to 100-120 bpm - shortens QT)
  5. Isoproterenol infusion (increases HR, shortens QT) - if no structural heart disease
  6. AVOID amiodarone (prolongs QT further - contraindicated in TdP)
  7. AVOID sotalol, procainamide

---

Perioperative Bradyarrhythmias

---

QUESTION 4: Clinical Features & Management of Total Spinal Anesthesia

Definition

• Intended spinal with excess drug/volume
• Accidental intrathecal injection during epidural placement
• Accidental intrathecal injection during interscalene or paravertebral block

---

Mechanism

NORMAL SPINAL (T4-T10) → Total Spinal
  ↓
LA spreads to cervical cord
  ↓
C3-C5 (phrenic nerve) blockade → Diaphragmatic paralysis → Apnea
Cervical sympathetics blocked → Extreme vasodilation + Bradycardia
Brainstem involvement → Loss of consciousness
  ↓
TOTAL SPINAL

• Excess volume or dose
• Baricity mismatch (hyperbaric in Trendelenburg, hypobaric in reverse Trendelenburg)
• Increased intra-abdominal pressure (pregnancy, ascites, obesity)
• Rapid injection
• Patient repositioning immediately after injection
• Accidental intrathecal through epidural catheter (entire epidural dose → intrathecal)

---

Clinical Features

SEQUENCE OF EVENTS IN TOTAL SPINAL:
────────────────────────────────────────────────────────

Level T4-T2:
  → Loss of intercostal respiration
  → Difficulty breathing ("I can't breathe" complaint)
  → Anxiety, agitation

Level C3-C5:
  → DIAPHRAGMATIC PARALYSIS → APNEA
  → Patient goes quiet, stops talking (SIGN - don't ignore!)

Sympathetic Block (T1-L2 all blocked):
  → Profound vasodilation → ↓ SVR → SEVERE HYPOTENSION
  → Cardioaccelerator fibers (T1-T4) blocked → BRADYCARDIA (can be profound)
  → Possible cardiac arrest

Brainstem/Cerebral involvement:
  → LOSS OF CONSCIOUSNESS
  → Nausea/vomiting (first sign often)
  → Miosis, ptosis (Horner's)

SUMMARY TABLE:
  Nausea/vomiting (vagal, falling BP)
  Anxiety ("I can't breathe")
  ↑ Sensory level (rapidly rising)
  ↓ Motor power in arms
  Apnea (C3-C5 involvement)
  Hypotension + Bradycardia
  Loss of consciousness
  Cardiac arrest (if untreated)

---

Management

TOTAL SPINAL - EMERGENCY MANAGEMENT
════════════════════════════════════════════════════════

IMMEDIATE:
  ① CALL FOR HELP
  ② 100% O₂ - FACE MASK FIRST
  ③ ASSESS AIRWAY AND BREATHING

AIRWAY + BREATHING:
  → If spontaneous breathing inadequate: POSITIVE PRESSURE VENTILATION (BVM)
  → INTUBATE IMMEDIATELY (RSI if time allows; bag-mask if apneic and hypotensive)
  → Goal: SpO₂ > 95%, EtCO₂ 35-40 mmHg
  → IPPV with 100% O₂

CARDIOVASCULAR SUPPORT:
  → HYPOTENSION:
    • IV fluid bolus: 500-1000 mL crystalloid RAPIDLY
    • EPHEDRINE 6-12 mg IV boluses (both α and β agonist - preferred in spinal hypotension)
      OR
    • PHENYLEPHRINE 50-100 mcg IV boluses (α₁ agonist)
    • If refractory → EPINEPHRINE (Adrenaline) 0.1-0.5 mg IV
    • NOREPINEPHRINE infusion (if vasopressor support needed)
    • Position: LEFT LATERAL TILT if pregnant; supine flat or Trendelenburg
  
  → BRADYCARDIA:
    • ATROPINE 0.5-1.0 mg IV (glycopyrrolate 0.2 mg IV)
    • If severe bradycardia + hypotension: EPINEPHRINE 0.1 mg IV
    • Isoproterenol / Dopamine for persistent bradycardia
  
  → CARDIAC ARREST:
    • FULL ACLS / BLS protocol
    • Chest compressions + Defibrillation if VF
    • Epinephrine 1 mg IV q 3-5 min

UNCONSCIOUS PATIENT:
  → Secure airway (RSI: Propofol 1-1.5 mg/kg + Succinylcholine 1.5 mg/kg)
  → Protect from aspiration
  → Maintain on IPPV until block regresses

MONITORING:
  → Continuous ECG, pulse oximetry, NIBP every 2 min
  → Invasive arterial line if available
  → Serial neurological assessment as block regresses

DURATION:
  → Total spinal resolves as LA metabolized
  → Bupivacaine: 2-4 hours
  → Lidocaine: 1-2 hours
  → Maintain ventilation and cardiovascular support throughout
  → Patient can be extubated when:
    • Fully awake (obeys commands)
    • SpO₂ adequate on spontaneous ventilation
    • BP and HR stable
    • Block regressed to ≤ T10

---

Prevention of Total Spinal

1. Aspirate epidural catheter before every dose (blood, CSF)
2. Test dose through epidural catheter: 3 mL of 2% lignocaine + adrenaline 1:200,000 (↑ HR if intravascular; rapid dense block if intrathecal)
3. Inject epidural in small incremental doses (3-5 mL at a time)
4. Know total safe intrathecal dose and never exceed
5. Barbotage and patient positioning considerations after spinal
6. Aspirate before injecting spinal (confirm free CSF flow)

---

QUESTION 5A: Soft Drugs in Anesthesia

Definition

• Predictable, rapid offset regardless of organ function
• Minimal accumulation
• "Context-insensitive" pharmacokinetics

---

Examples of Soft Drugs in Anesthesia

1. Remifentanil (Most Important Example)

• Class: Ultra-short-acting opioid (fentanyl family)
• Metabolism: Esterases in plasma and tissue (non-specific esterases)
• Elimination t½: 3-5 minutes (independent of infusion duration)
• CSHT: ~3-4 minutes (does NOT increase with longer infusions)
• Context-sensitive: NO (unique among opioids)
• Metabolite: Remifentanil acid (1/4600 potency - inactive clinically)
• Advantages: Predictable rapid offset, ideal for short procedures, allows rapid neurological assessment, used in TIVA
• Disadvantages: Acute opioid tolerance, hyperalgesia after stopping, NO postoperative analgesia (must plan bridge analgesia)
• Use in organ failure: Safe in renal and hepatic failure (no dose adjustment needed)

2. Cisatracurium (and Atracurium)

• Class: Non-depolarizing NMB (intermediate duration)
• Metabolism: Hofmann elimination (spontaneous, pH and temperature-dependent) + ester hydrolysis
• No enzyme required, no organ involvement
• Atracurium: Metabolite laudanosine (CNS excitant at high doses in ICU - rare clinical significance)
• Cisatracurium: 4x more potent than atracurium; LESS laudanosine production (preferred)
• Ideal in renal failure, hepatic failure, ICU patients (ARDS, prolonged infusion)
• Temperature sensitivity: Hypothermia prolongs Hofmann elimination → longer block

3. Esmolol

• Class: Ultra-short-acting β₁-selective blocker
• Metabolism: Red blood cell esterases (not plasma cholinesterase)
• t½: 9-10 minutes
• Use: Intraoperative hypertension and tachycardia, controlled hypotension, rate control in AF
• Context-insensitive - predictable offset

4. Clevidipine

• Class: Dihydropyridine calcium channel blocker (arterial vasodilator)
• Metabolism: Plasma and tissue esterases
• t½: ~1 minute
• Use: Acute perioperative hypertension management
• Predictable, titratable BP control

5. Remimazolam

• Class: Benzodiazepine (GABA-A agonist) - "soft" benzodiazepine
• Metabolism: Tissue esterases to inactive metabolite (CNS 7054 - 1/300 potency)
• t½: 40-60 minutes
• Reversal: Flumazenil (like all benzodiazepines)
• Advantage over midazolam: Much shorter and predictable duration
• Use: Procedural sedation, induction in high-risk patients
• Context-insensitive

6. Methohexital (Methohexitone)

• Not classically a "soft drug" by metabolism but faster hepatic metabolism than thiopental
• Used for ECT (short duration needed)

Summary Table

---

QUESTION 5B: Post-Thyroidectomy Complications & Management

Overview

---

Classification: Early vs. Late

EARLY (within 24-48 hr):          LATE (weeks to months):
──────────────────────────────     ──────────────────────────
1. Hematoma/hemorrhage             1. Hypothyroidism
2. Airway obstruction              2. Permanent hypoparathyroidism
3. Hypocalcemia (acute)            3. Keloid scarring
4. Recurrent laryngeal nerve injury 4. Late tracheomalacia
5. Respiratory distress            5. Wound infection
6. Thyroid storm                   6. Chyle leak (neck dissection)
7. Pneumothorax (rare)

---

1. Hematoma / Neck Hemorrhage - MOST DANGEROUS EARLY COMPLICATION

MANAGEMENT OF POST-THYROIDECTOMY HEMATOMA:
  ↓
Rapid assessment: Is airway compromised?
  ↓ YES (stridor, SpO₂ falling, respiratory distress)
  ↓
BEDSIDE EMERGENCY DECOMPRESSION:
  → Open wound IMMEDIATELY (at bedside if necessary)
  → Remove clips/sutures to release hematoma
  → This alone may relieve obstruction (venous congestion relieved)
  → Call for surgeon + anesthesiologist

  ↓ (if not immediately relieved)
AIRWAY MANAGEMENT:
  → Senior anesthesiologist + surgical team together
  → Try Awake FOB first if patient cooperative
  → If rapidly deteriorating: Inhalation induction with sevoflurane
    (maintain spontaneous ventilation until intubated)
  → AVOID NEUROMUSCULAR BLOCKADE until airway secured
    (edema + hematoma = can't intubate, can't mask)
  → Difficult airway cart at bedside; surgeon for surgical airway
  ↓
Return to theatre for formal hemostasis

2. Recurrent Laryngeal Nerve (RLN) Injury

• Ipsilateral vocal cord paralysis in paramedian position
• Hoarse voice (breathy quality), aspiration of liquids
• Usually temporary (neuropraxia) - resolves in weeks to months
• Permanent injury: 1% of thyroidectomies
• Diagnosis: Laryngoscopy

• BOTH cords in paramedian position
• Stridor on extubation or within hours
• Life-threatening airway obstruction
• Management: Emergency tracheostomy or reintubation

• Weakness of cricothyroid muscle
• High pitch singing affected (Amelita Galli-Curci's voice changed after thyroidectomy)
• Subtle - often missed clinically

---

3. Hypocalcemia (Hypoparathyroidism)

MILD (Ca²⁺ 2.0-2.1 mmol/L):
  → Perioral tingling, fingertip numbness
  → Chvostek's sign (+): Tap facial nerve → Facial muscle twitch
  → Trousseau's sign (+): Inflate BP cuff 20 mmHg above systolic for 3 min → Carpal spasm (most sensitive)

MODERATE (Ca²⁺ 1.8-2.0 mmol/L):
  → Muscle cramps, tetany
  → Laryngospasm (DANGEROUS - can occur at any time post-op)
  → Bronchospasm

SEVERE (Ca²⁺ < 1.75 mmol/L):
  → Seizures
  → Cardiac arrhythmias (Q-T prolongation → TdP)
  → Hypotension

• Symptomatic / Severe: IV Calcium gluconate 10 mL of 10% (90 mg elemental Ca) over 10 min IV → Then infusion: 0.5-2 mg/kg/hr elemental Ca in D5W → NOT calcium chloride peripherally (tissue necrosis)
• Oral (mild/maintenance): Calcium carbonate 1-2 g TDS + Calcitriol (active vitamin D) 0.25-1 mcg/day
• Monitor: Serum Ca²⁺ and phosphate q 6-12 hr initially, then daily
• Long-term hypoparathyroidism: Recombinant PTH (Natpara) emerging treatment

---

4. Thyroid Storm (Thyrotoxic Crisis)

1. β-BLOCKER: Propranolol 60-80 mg PO q4h OR IV esmolol (HR control)
2. THIONAMIDE: Propylthiouracil (PTU) 200 mg q4h OR Methimazole 20 mg q4h
   (Blocks NEW synthesis - NOT existing stores)
3. IODINE (Lugol's 5-10 drops q6-8h): GIVE 1 HOUR AFTER THIONAMIDE
   (Wolff-Chaikoff effect - blocks hormone release)
   (If given before thionamide → provides substrate → worsens thyroid storm)
4. HYDROCORTISONE 100 mg IV q8h (blocks T4→T3 conversion; relative adrenal insufficiency)
5. DANTROLENE 2-3 mg/kg (if hyperthermia severe/malignant hyperthermia overlap)
6. COOLING: Paracetamol (NOT salicylates - ↑ free T4), ice packs
7. SUPPORTIVE: IV fluids, electrolytes, oxygen, ICU admission

---

5. Tracheomalacia

• Rare complication after long-standing large goiter
• Chronic tracheal compression weakens cartilage rings
• On removing thyroid → Trachea collapses (no external support)
• Presentation: Stridor immediately on extubation ("tracheal collapse")
• Prevention: Keep intubated initially; elective tracheostomy in severe cases
• Management: Reintubation; posterior tracheopexy or tracheostomy

---

QUESTION 6A: Brain Death Diagnosis

Definition

---

Prerequisites (Before Testing)

1. CAUSE ESTABLISHED:
   → Known, irreversible structural brain injury (head trauma, subarachnoid hemorrhage,
     hypoxic-ischemic injury, etc.)

2. CONFOUNDERS EXCLUDED:
   → Hypothermia: Core temperature > 35°C (normothermia mandatory)
   → Hypotension: MAP > 60 mmHg (adequate cerebral perfusion pressure)
   → Sedatives/CNS depressants: Adequate time elapsed (5 half-lives)
     (Wait longer for renal/hepatic failure patients)
   → Neuromuscular blocking agents: 4 twitches on TOF, or wait 4 half-lives
   → Metabolic/endocrine: No severe hypoglycemia, hypo/hypernatremia,
     severe acid-base disturbance, hepatic encephalopathy
   → Drug intoxication (alcohol, barbiturates, tricyclics)

---

Clinical Brain Death Testing (India: Two Doctors, Two Separate Examinations, 6 Hours Apart)

• Examination must be performed by panel of 4 doctors in a registered institution:
  1. Authorized medical officer (nominated by hospital)
  2. Neurologist or neurosurgeon
  3. Anesthesiologist or intensivist
  4. Physician (treating doctor) - can be one of the above

---

A. Tests for Absence of Brainstem Reflexes

CRANIAL NERVE TESTING:
──────────────────────────────────────────────────────────

1. PUPILLARY LIGHT REFLEX (CN II afferent, CN III efferent):
   → Pupils: Fixed, dilated (4-9 mm)
   → No response to direct or consensual light
   → Note: Atropine, mydriatics can mimic - exclude pharmacological cause

2. CORNEAL REFLEX (CN V afferent, CN VII efferent):
   → Touch cornea with cotton wisp / sterile saline drops
   → No blink response bilaterally

3. OCULOCEPHALIC REFLEX / "DOLL'S EYE" (CN VIII, CN III, CN VI):
   → Contraindicated if cervical spine injury
   → Rapidly rotate head side to side
   → Normal response: Eyes move opposite to head (doll's eyes +)
   → Brain dead: Eyes move WITH the head (no reflex - doll's eyes ABSENT)

4. OCULOVESTIBULAR REFLEX / COLD CALORIC (CN VIII afferent, CN III/VI efferent):
   → MOST SENSITIVE brainstem test
   → Prerequisites: Head 30° elevation, tympanic membranes intact
   → Inject 50 mL ice-cold water into each ear (wait 5 min between sides)
   → Normal (awake): Fast phase nystagmus AWAY from cold water (COWS: Cold Opposite, Warm Same)
   → Comatose with intact brainstem: Slow conjugate eye deviation TOWARD cold ear
   → BRAIN DEAD: NO eye movement at all

5. GLOSOPHARYNGEAL/VAGAL REFLEX - GAG REFLEX (CN IX, X):
   → Stimulate posterior pharynx with suction catheter
   → No gag response

6. COUGH REFLEX (CN X via trachea):
   → Deep suction catheter into trachea/carina via ETT
   → No cough response

7. FACIAL RESPONSE TO PAIN:
   → Supraorbital pressure, nail bed pressure
   → No grimacing, no facial movement

---

B. Apnea Test (Most Important Confirmatory Test)

APNEA TEST PROCEDURE:
─────────────────────────────────────────────────────────
PREREQUISITES:
  → pH ≥ 7.40, PaCO₂ 35-45 mmHg (normocapnia)
  → SpO₂ ≥ 95%
  → BP stable (MAP ≥ 60 mmHg)
  → Normothermia > 35°C

PROCEDURE:
  1. Pre-oxygenate with 100% O₂ for 10 min
  2. Reduce PEEP to ≤5 cmH₂O
  3. Disconnect ventilator
  4. Insert suction catheter through ETT → Deliver O₂ at 6 L/min
     (Apneic oxygenation - maintains SpO₂, allows CO₂ to rise)
  5. OBSERVE for 8-10 minutes for ANY spontaneous respiratory effort
  6. Draw ABG at end of observation

RESULT INTERPRETATION:
  → POSITIVE APNEA TEST (supports brain death):
    PaCO₂ rises to ≥ 60 mmHg (or ≥ 20 mmHg above baseline)
    NO respiratory effort observed
  → NEGATIVE: Any respiratory movement = NOT brain dead
  → ABORT test if: SpO₂ < 85%, BP falls, arrhythmia
    → Draw ABG, reconnect ventilator, interpret with caution

---

C. Ancillary / Confirmatory Tests (Not Mandatory in India, Used When Clinical Tests Incomplete)

---

Spinal Cord Reflexes - Important Point

• Spontaneous limb movements ("Lazarus sign")
• Plantar response
• Deep tendon reflexes
• These do NOT indicate brain function

---

QUESTION 6B: ECT - Anesthetic Management

Introduction

• Severe/refractory major depression
• Acute mania with severe agitation
• Catatonia (schizophrenia)
• Severe depression in pregnancy (safe alternative to drugs)
• Neuroleptic malignant syndrome

1. Prevent awareness and distress
2. Modify convulsion (prevent musculoskeletal injury)
3. Manage autonomic side effects
4. Maintain airway and oxygenation during apnea

---

Physiological Changes During ECT Seizure

SEQUENCE OF EVENTS:
─────────────────────────────────────────────────────────

INITIAL (0-30 seconds after shock):
  → Parasympathetic (vagal) surge: BRADYCARDIA, transient hypotension
  → Can cause: Asystole (brief), bradycardia

ICTAL PHASE (seizure, 20-120 seconds):
  → Sympathetic surge: HYPERTENSION (SBP can rise 30-40%), TACHYCARDIA
  → ↑ Cerebral blood flow, ↑ ICP
  → ↑ IOP
  → ↑ Intragastric pressure

POST-ICTAL (minutes after):
  → Gradual return to baseline
  → Apnea during seizure requires airway management
  → Confusion, headache common

---

Pre-ECT Assessment

• Psychiatric history, current medications
• Continue most psychiatric medications (lithium - stop 24-48 hr before; MAOIs - discuss with psychiatrist; benzodiazepines - reduce seizure threshold - consider dose reduction)
• Cardiovascular: ECG, BP, arrhythmias, recent MI/stroke (relative contraindication)
• Airway: Modified fasting (6 hr solid, 2 hr clear liquids - outpatient ECT)
• Medications that affect seizure duration:
  • Shorten: Benzodiazepines, anticonvulsants, lithium, high-dose opioids
  • Prolong: Theophylline, caffeine, ketamine

---

Anesthetic Agents for ECT

Induction Agents

Muscle Relaxant (Modification)

• Succinylcholine 0.5-1.0 mg/kg IV - Gold standard
  • Short duration (2-3 min) - seizure modification without prolonged paralysis
  • Prevents violent convulsions → prevents fractures, dislocations
  • Complete relaxation achieved before electrical stimulus
  • If succinylcholine contraindicated: Mivacurium (short-acting) or Rocuronium + Sugammadex

Anticholinergic Premedication

• Glycopyrrolate 0.2 mg IV (preferred) or Atropine 0.4-0.6 mg IV
• Given before induction to prevent vagally-mediated bradycardia at onset of seizure

---

ECT Procedure - Anesthetic Steps

SETUP:
  Anesthesia machine check, crash cart available
  IV access, monitoring: ECG, SpO₂, NIBP, EEG (seizure monitoring by psychiatrist)
  Bite block to protect teeth

PRE-MEDICATION:
  Glycopyrrolate 0.2 mg IV (anticholinergic)
  Oxygen by mask (2-3 min pre-oxygenation)

INDUCTION:
  Propofol 1.0-1.5 mg/kg IV (titrate)
  Succinylcholine 0.5-1.0 mg/kg IV
  Face mask + gentle positive pressure (O₂)
  Allow fasciculations to subside

BITE BLOCK inserted by psychiatrist

ELECTRICAL STIMULUS delivered

SEIZURE:
  Observe modified convulsion (minimal limb movement)
  Airway maintained by anesthesiologist
  Oxygenation maintained throughout

POST-ICTAL:
  Patient apneic and unconscious initially
  Continue gentle assisted ventilation
  Await return of spontaneous ventilation
  Place in recovery position when awake

RECOVERY:
  Monitor: ECG, SpO₂, BP for 20-30 min
  PONV: Ondansetron prophylaxis
  Headache: Paracetamol
  Confusion: Reassure (post-ictal state - normal)
  Can be discharged home once fully awake (outpatient ECT)

---

Special Situations in ECT

---

QUESTION 7A: Erector Spinae Plane (ESP) Block

Anatomy

CROSS-SECTION AT THORACIC LEVEL:

Skin
  ↓
Trapezius
  ↓
Rhomboid major
  ↓
ERECTOR SPINAE MUSCLE (Longissimus + Iliocostalis)
  ↓
[ESP BLOCK TARGET - Fascial plane here]
  ↓
TRANSVERSE PROCESS / COSTOTRANSVERSE JUNCTION
  ↓
Rib / Paravertebral space
  ↓
Pleura (anteriorly)

LOCAL ANESTHETIC SPREAD:
  → Cephalad and caudal in the ESP
  → Passes around transverse process → Enters paravertebral space
  → Blocks dorsal AND ventral rami of spinal nerves
  → Also thought to block sympathetic chain
  → Bilateral injection: Covers large thoracic/abdominal territory

---

Mechanism of Action

1. Spreads in the ESP fascial plane (cephalocaudal)
2. Tracks around transverse process through intertransverse ligaments
3. Reaches paravertebral space → blocks ventral ramus (intercostal nerve)
4. Blocks dorsal ramus (back pain)
5. May reach epidural space with large volumes

---

Ultrasound Technique

POSITION: Sitting or lateral decubitus (thoracic) or prone (lumbar)

PROBE: Linear (superficial, thin patient) or curvilinear (deeper, obese)

SCANNING:
  → Transverse: Identify spinous process, slide laterally 2-3 cm
  → Tilt probe medially: Identify transverse process (flat hyperechoic line)
  → "Three-muscle sign": Identify trapezius/rhomboid, erector spinae on TP
  → Sagittal/parasagittal scan: TP appears as "castle battlements"

INJECTION:
  → In-plane: Caudal to cephalad (or cranial to caudal)
  → Needle tip: Between TP and deep surface of erector spinae
  → Confirm spread: "Lifting" of erector spinae off TP
  → Volume: 20-30 mL per level (for thoracic spread)
  → Bilateral for midline surgeries

LEVELS:
  → T4-T5: Upper thorax, breast surgery
  → T5-T9: Chest (pneumonectomy, lobectomy, rib fixation)
  → T7-T9: Upper abdomen (hepatobiliary, upper GI)
  → L1-L4: Lumbar/lower abdominal (hip, lumbar)

---

Clinical Applications

---

Advantages of ESP Block

1. Safety: No direct contact with pleura, neuraxial structures, or vascular structures
2. Ease: Technically simpler than paravertebral block or TPVB
3. Versatility: Works from cervical to sacral level
4. Continuous catheter: Ideal for prolonged pain management
5. Bilateral: Can be done bilaterally (unlike epidural timing concerns with anticoagulation)
6. Opioid-sparing: Significant reduction in perioperative opioid consumption
7. ERAS integration: Facilitates enhanced recovery protocols

Limitations

• Mechanism still debated (variable spread to paravertebral space)
• Variable efficacy (not as reliable as neuraxial for complete block)
• Large volumes required (30-40 mL per side)
• Some studies show inconsistent dermatomal spread
• Motor block: Rarely causes motor weakness (dorsal rami block → paraspinal weakness)

---

QUESTION 7B: Opioid-Free Anesthesia (OFA)

Definition

---

Rationale for OFA

PROBLEMS WITH OPIOIDS:
────────────────────────────────────────────────────────
INTRAOPERATIVE:
  → Respiratory depression
  → Postoperative nausea and vomiting (PONV) - most common
  → Muscle rigidity (chest wall - high-dose fentanyl)
  → Cardiovascular instability (bradycardia, hypotension with remifentanil)

POSTOPERATIVE:
  → Postoperative Nausea and Vomiting (PONV)
  → Postoperative ileus (gastroparesis, delayed GI recovery)
  → Urinary retention
  → Respiratory depression (especially in OSA, elderly)
  → Pruritus
  → Sedation, cognitive impairment
  → Opioid-induced hyperalgesia (OIH) - especially with remifentanil
  → Tolerance and withdrawal
  → Immunosuppression (potential - ongoing research)
  → Opioid use disorder potential (chronic pain patients)

---

Components of OFA (Multimodal Analgesic Framework)

OFA FRAMEWORK:
────────────────────────────────────────────────────────────────

1. REGIONAL ANESTHESIA (NEURAL BLOCKADE - most important component)
   → Peripheral nerve blocks (ESP, TAP, femoral, interscalene, etc.)
   → Neuraxial (spinal/epidural with LA only)
   → Goal-directed regional to cover surgical site

2. SYSTEMIC NON-OPIOID ANALGESICS
   ┌────────────────────────────────────────────────────────────────┐
   │ a. PARACETAMOL (Acetaminophen): 15 mg/kg IV q6h                │
   │    Mechanism: COX-3 inhibition, serotonergic pathway           │
   │                                                                 │
   │ b. NSAIDs / COX-2 inhibitors: Diclofenac, ketorolac, celecoxib │
   │    Mechanism: Prostaglandin synthesis inhibition                │
   │    → Most powerful synergist with paracetamol                  │
   │                                                                 │
   │ c. DEXMEDETOMIDINE: α₂ agonist                                 │
   │    → Excellent analgesic-sparing; reduces MAC by 30-50%        │
   │    → Intraop infusion: 0.4-0.7 mcg/kg/hr                      │
   │    → Reduces opioid requirements 50-80% in various studies     │
   │    → Bonus: Anxiolysis, antishivering, sympatholysis           │
   │                                                                 │
   │ d. KETAMINE (sub-anesthetic/analgesic doses):                  │
   │    → NMDA receptor antagonism → Central sensitization block    │
   │    → 0.1-0.5 mg/kg IV bolus; 0.1-0.3 mg/kg/hr infusion        │
   │    → Reduces post-op opioid consumption significantly          │
   │    → Prevents opioid-induced hyperalgesia                      │
   │                                                                 │
   │ e. LIDOCAINE INFUSION:                                         │
   │    → 1.5 mg/kg bolus → 1-2 mg/kg/hr infusion                  │
   │    → Na⁺ channel block + anti-inflammatory                     │
   │    → Reduces MAC, opioid consumption, PONV, ileus duration     │
   │    → Monitor ECG continuously                                  │
   │                                                                 │
   │ f. MAGNESIUM SULFATE:                                          │
   │    → 30-50 mg/kg IV bolus → 6-10 mg/kg/hr infusion            │
   │    → NMDA antagonist (similar to ketamine)                     │
   │    → Reduces MAC + opioid consumption                          │
   │    → Monitor: Deep tendon reflexes, UO                         │
   │                                                                 │
   │ g. GABAPENTINOIDS: Pregabalin 150 mg or Gabapentin 600-900 mg  │
   │    → Given 1-2 hr pre-op (premedication)                       │
   │    → ↓ Ca²⁺ channel current → ↓ nociceptive transmission      │
   │    → Reduces opioid use post-op; may cause dizziness/sedation  │
   │                                                                 │
   │ h. GLUCOCORTICOIDS: Dexamethasone 4-8 mg IV at induction       │
   │    → Anti-inflammatory analgesic + antiemetic                  │
   │    → Part of ERAS protocols routinely                          │
   └────────────────────────────────────────────────────────────────┘

3. GENERAL ANESTHETIC TECHNIQUE
   → TIVA (propofol) preferred (↓ PONV vs volatile)
   → Volatile agent at lower concentrations (regional supplement)
   → Dexmedetomidine reduces MAC significantly

4. ADJUNCTS
   → Clonidine (α₂ agonist, less potent than dexmedetomidine)
   → Melatonin (premedication - anxiolysis, opioid-sparing)
   → Glucosamine, ascorbic acid (less evidence)

---

Indications for OFA (Strongest Evidence)

1. Bariatric surgery (morbid obesity → opioids catastrophic for OSA)
2. Opioid-dependent patients (tolerance makes opioids ineffective; OFA with ketamine excellent)
3. Chronic pain patients (prevent opioid-induced hyperalgesia)
4. OSA / Sleep disordered breathing (respiratory depression risk)
5. Post-mastectomy / Breast surgery (PONV catastrophic for patient experience)
6. Scoliosis surgery / Spine surgery (neuromonitoring - opioids interfere with MEP/SSEP)
7. ERAS protocols (colorectal, hepatobiliary, thoracic)
8. Opioid naive patients (avoid first exposure and dependence)

---

OFA Limitations

• Complex drug regimen (more drugs to monitor)
• Dexmedetomidine → Bradycardia, hypotension
• Ketamine → Emergence phenomena in higher doses
• Intraoperative hypertension/tachycardia if regional block inadequate (must have rescue plan)
• Requires regional anesthesia skills
• Not appropriate for all surgeries (e.g., major cardiac, complex neurosurgery)

---

QUESTION 8A: EuroSCORE

Definition

---

Versions

---

Variables in EuroSCORE II (Three Categories)

Category 1: Patient-Related Factors (6 variables)

Category 2: Cardiac-Related Factors (5 variables)

Category 3: Operation-Related Factors (5 variables)

---

Risk Stratification

---

Clinical Use

1. Preoperative counseling: Discuss operative mortality risk with patient/family
2. Surgical decision-making: High EuroSCORE → consider TAVI over surgical AVR, OPCAB over conventional CABG
3. ICU planning: High-risk patients need more intensive perioperative management
4. Institutional benchmarking: Compare outcomes across centers (O:E ratio)
5. TAVI decision: EuroSCORE II + STS score used by Heart Team for TAVR eligibility

---

Limitations of EuroSCORE II

• Derived from Western European populations - may overestimate risk in some populations
• Doesn't capture frailty well (increasingly important in elderly cardiac patients)
• STS (Society of Thoracic Surgeons) score is an alternative (more commonly used in USA)
• Does not predict stroke, renal failure, prolonged ventilation - only mortality

---

QUESTION 8B: Golden Hour in Acute Trauma Care

Concept

---

Trimodal Distribution of Trauma Deaths (Dr. Donald Trunkey)

TRIMODAL DISTRIBUTION:
──────────────────────────────────────────────────────────
PEAK 1 (Seconds to minutes):
  → 50% of trauma deaths
  → Causes: Severe brain injury, brainstem injury, high cervical cord injury,
    aortic rupture, cardiac rupture
  → PREVENTABLE ONLY BY PREVENTION

PEAK 2 (Minutes to hours = THE GOLDEN HOUR):
  → 30% of trauma deaths
  → Causes: Subdural/epidural hematoma, hemopneumothorax, splenic/hepatic laceration,
    pelvic fracture, multiple injuries with significant blood loss
  → MOST PREVENTABLE with early, definitive care → Rationale for golden hour

PEAK 3 (Days to weeks):
  → 20% of trauma deaths
  → Causes: Sepsis, ARDS, multiple organ failure, pneumonia
  → Preventable with good ICU care, infection control

---

ATLS (Advanced Trauma Life Support) - Systematic Approach Within Golden Hour

Primary Survey: ABCDE (Life-Threatening Problems Addressed Simultaneously)

A - AIRWAY (with C-spine protection)
  → Assess: Speaking? Stridor? Gurgling?
  → Open airway: Jaw thrust (not head tilt) + suction
  → C-spine: Manual inline stabilization → Hard collar + blocks + tape
  → Definitive: RSI + ETT if GCS ≤8, airway threat, anticipated deterioration
  → Surgical airway: Cricothyrotomy if "can't intubate, can't oxygenate"

B - BREATHING AND VENTILATION
  → Inspect: RR, symmetry, paradoxical movement, penetrating wounds
  → Auscultate both sides
  → IMMEDIATE THREATS - treat NOW:
    • Tension pneumothorax: Needle decompression (2nd ICS MCL) → chest drain
    • Open pneumothorax: 3-sided occlusive dressing → chest drain
    • Massive hemothorax: 2 large IVs + chest drain (32-36 Fr)
    • Flail chest: O₂, analgesia; IPPV if failing
  → SpO₂ + ETCO₂ if intubated

C - CIRCULATION (with hemorrhage control)
  → Assess: HR, BP, cap refill, skin color, consciousness
  → HEMORRHAGE CONTROL:
    • External: Direct pressure, tourniquet (limb), wound packing (junctional)
    • Internal: Urgent surgical intervention (DAMAGE CONTROL)
  → IV ACCESS: 2 large-bore peripherals (min 16G) or IO
  → FLUID RESUSCITATION:
    → DAMAGE CONTROL RESUSCITATION:
      • PERMISSIVE HYPOTENSION (SBP 80-90 mmHg) until hemorrhage control
      • BALANCED HEMOSTATIC RESUSCITATION: pRBC:FFP:Platelets = 1:1:1
      • TRANEXAMIC ACID 1g IV over 10 min within 3 hours of injury (CRASH-2 trial)
      • Avoid large volumes of crystalloid (hemodilution + coagulopathy)

D - DISABILITY (Neurological)
  → GCS score (E4V5M6 = 15)
  → Pupils: Size, reactivity, symmetry
  → Blood glucose (hypoglycemia → altered GCS)
  → Signs of herniation: Cushing's triad (Bradycardia + Hypertension + Irregular respirations)

E - EXPOSURE / ENVIRONMENT
  → Fully expose patient (log roll + full examination)
  → Prevent hypothermia (warm blankets, warm fluids, warm environment)
  → HYPOTHERMIA = Lethal triad (Hypothermia + Acidosis + Coagulopathy)

---

The Lethal Triad of Trauma

          HEMORRHAGIC SHOCK
                ↓
    ┌───────────┼───────────┐
    ↓           ↓           ↓
HYPOTHERMIA   ACIDOSIS   COAGULOPATHY
    │           │           │
    └───────────┴───────────┘
           Each worsens
           the other two
         → DEATH if not broken
         
BREAK THE CYCLE:
  → Warm ALL fluids; warm environment; active warming
  → Correct acidosis (resuscitation, buffer therapy cautiously)
  → Blood products 1:1:1 + TXA + calcium supplementation

---

Damage Control Resuscitation vs Damage Control Surgery

---

Secondary Survey

---

QUESTION 9A: Anaphylaxis Management

Definition

• Skin/mucosal involvement (urticaria, flushing, angioedema) - 80% of cases
• Plus: Respiratory compromise (bronchospasm, stridor) AND/OR
• Cardiovascular compromise (hypotension, tachycardia, shock)

---

Classification

---

Common Perioperative Triggers

MOST COMMON PERIOPERATIVE CAUSES (ranked):
1. Neuromuscular blocking agents (NMBAs) - 60-70% of cases
   → Rocuronium most common (most used)
   → Succinylcholine, vecuronium, atracurium
   → Cross-reactivity between NMBAs (20-60%)

2. Antibiotics - 15-20%
   → Penicillins, cephalosporins (cross-reactivity ~2%)
   → Most common: Ampicillin/amoxicillin

3. Latex - < 5% (decreasing, latex-free protocols)
   → Risk: Healthcare workers, spina bifida patients, atopics

4. Chlorhexidine - increasing recognition
   → Surgical prep, catheter coatings, wound dressings

5. Colloids - Gelofusine, albumin, dextran

6. NSAIDs, Aspirin

7. Opioids (usually anaphylactoid - direct mast cell)

8. Patent Blue/Methylene Blue dye (sentinel lymph node biopsy)

---

Clinical Features and Grading (Ring & Messmer)

---

Management

PERIOPERATIVE ANAPHYLAXIS MANAGEMENT
════════════════════════════════════════════════════════════

STEP 1: RECOGNITION
  → Sudden unexplained cardiovascular collapse ± bronchospasm
  → Urticaria (may be hidden under drapes - check skin!)
  → Hypotension + tachycardia after drug administration

STEP 2: STOP TRIGGER
  → Stop ALL suspected drugs/infusions
  → Remove latex materials from field (if latex suspected)
  → MAINTAIN ANESTHESIA (light anesthetic - prevent awareness)

STEP 3: CALL FOR HELP
  → Inform surgeon: Pause/abandon surgery if possible

STEP 4: EPINEPHRINE (ADRENALINE) - FIRST LINE, NO DELAY
  ┌─────────────────────────────────────────────────────────┐
  │ GRADE II-III: 0.1-0.5 mg EPINEPHRINE IV (IV route!)   │
  │ (10-50 mcg/kg in children)                             │
  │ Dilute: 1 mg in 10 mL = 0.1 mg/mL → give 1-5 mL IV   │
  │ Repeat every 5 min if needed                           │
  │                                                        │
  │ GRADE IV (cardiac arrest): 1 mg IV → ACLS protocol    │
  │                                                        │
  │ If no IV access: 0.3-0.5 mg IM (anterolateral thigh)  │
  └─────────────────────────────────────────────────────────┘
  Mechanism of epinephrine:
  → α₁: Vasoconstriction (reverses vasodilation/angioedema)
  → β₁: ↑ HR and contractility (reverses cardiovascular collapse)
  → β₂: Bronchodilation (reverses bronchospasm)
  → Inhibits mast cell degranulation (β₂)

STEP 5: AIRWAY + O₂
  → 100% O₂
  → If not already intubated: Intubate NOW (especially with angioedema - can obstruct rapidly)
  → IPPV

STEP 6: IV FLUIDS
  → RAPID fluid bolus: 1-2 L crystalloid (0.9% NaCl) → repeat as needed
  → Aim MAP > 65 mmHg

STEP 7: SECONDARY TREATMENTS (AFTER EPINEPHRINE)
  ┌────────────────────────────────────────────────────────────┐
  │ ANTIHISTAMINES:                                            │
  │  H1 blocker: Chlorpheniramine 10 mg IV slow (UK)          │
  │              OR Diphenhydramine 50 mg IV (US)              │
  │  H2 blocker: Ranitidine 50 mg IV or Famotidine 20 mg IV   │
  │  Note: Do NOT give antihistamines INSTEAD of epinephrine   │
  │                                                            │
  │ CORTICOSTEROIDS (Prevent biphasic reaction):              │
  │  Hydrocortisone 200 mg IV                                  │
  │  OR Methylprednisolone 1-2 mg/kg IV                       │
  │  Onset: 4-6 hours (too slow for acute management)         │
  │                                                            │
  │ BRONCHOSPASM (if persists after epinephrine):             │
  │  Salbutamol MDI (via ETT) or nebulized (8-10 puffs)       │
  │  Ipratropium 500 mcg nebulized                             │
  │  IV aminophylline (refractory bronchospasm)                │
  │  Magnesium sulfate 2g IV (severe refractory)              │
  │                                                            │
  │ VASOPRESSOR INFUSION (if persistent hypotension):         │
  │  Noradrenaline 0.05-0.3 mcg/kg/min                        │
  │  Vasopressin 0.03 U/min (catecholamine-resistant shock)   │
  │                                                            │
  │ GLUCAGON 1-2 mg IV (β-blocker on board → poor epinephrine │
  │  response; glucagon bypasses β-receptor)                  │
  │                                                            │
  │ REFRACTORY ANAPHYLAXIS: Consider ECMO                     │
  └────────────────────────────────────────────────────────────┘

STEP 8: POST-RESUSCITATION
  → Monitor: 6-8 hr minimum (biphasic reaction risk)
  → Biphasic reaction: Second anaphylaxis wave 4-12 hr later (5-20% cases)
  → ICU admission for Grade III-IV
  → Blood samples for MAST TRYPTASE:
    • Sample 1: IMMEDIATELY (or as soon as possible)
    • Sample 2: 1-2 hours after reaction
    • Sample 3: >24 hr (baseline)
    → Elevated tryptase confirms mast cell activation (confirms anaphylaxis)
  → Referral to allergy clinic (skin prick testing, IgE RAST 4-6 weeks later)
  → Document SUSPECTED agent; MedicAlert bracelet
  → EPIPEN prescription if discharged

---

QUESTION 9B: Postoperative Delirium - Management

Definition

• Disturbance of attention and awareness
• Develops over a short period (hours to days) and fluctuates
• Cognitive change (memory, disorientation, language, perception)
• Not better explained by a pre-existing condition
• Evidence of an underlying medical cause

---

Subtypes

---

Risk Factors (Non-modifiable vs Modifiable)

PREDISPOSING FACTORS                 PRECIPITATING FACTORS
(Non-modifiable)                     (Modifiable - PREVENT THESE)
────────────────────────────────     ────────────────────────────────
Age > 70 years                       Sleep deprivation
Pre-existing dementia / MCI          Pain (inadequately treated)
Prior delirium episodes              Immobility
Depression / anxiety                 Urinary catheter / physical restraints
Hearing/vision impairment            Polypharmacy (especially anticholinergics, benzos)
Alcoholism                           Opioids (especially meperidine)
Dehydration                          Benzodiazepines
Malnutrition                         Steroids (high dose)
Chronic medical comorbidities        Metabolic: Hypo/hypernatremia, hypoglycemia,
Functional impairment                  hypocalcemia, uremia, hepatic failure
Major surgery (cardiac, ortho, GI)   Hypoxia / hypercapnia
ICU admission                        Hypothermia
                                     Sepsis
                                     Urinary retention / Constipation
                                     New environment (sensory deprivation)
                                     Anticholinergic drugs

---

Assessment Tools

1. CAM (Confusion Assessment Method) - Gold standard for non-ICU:
   • Feature 1: Acute onset AND fluctuating course
   • Feature 2: Inattention
   • Feature 3: Disorganized thinking
   • Feature 4: Altered level of consciousness
   • CAM positive = Features 1 + 2 + (3 OR 4)
2. CAM-ICU - For ventilated ICU patients (uses nonverbal signs)
3. RASS (Richmond Agitation-Sedation Scale) - Assess sedation/agitation level
4. 3D-CAM, 4AT - Bedside screening tools

---

Management

Non-Pharmacological (FIRST LINE - Most Effective)

HOSPITAL ELDER LIFE PROGRAM (HELP):
  ┌───────────────────────────────────────────────────────────┐
  │ ORIENTATION: Clock + calendar visible; remind date/time   │
  │ Familiar faces: Family at bedside (opens visiting hours)  │
  │ Communication aids: Hearing aids, glasses PROVIDED        │
  │ SLEEP PROTOCOL:                                           │
  │   → No unnecessary nighttime interruptions               │
  │   → Ear plugs, eye masks                                  │
  │   → Lights off at night; lighting change by day          │
  │   → Warm milk, relaxation music                          │
  │ EARLY MOBILIZATION:                                       │
  │   → Sit out of bed Day 1 post-op                         │
  │   → Remove catheters / IV lines ASAP                     │
  │   → Physiotherapy involvement                            │
  │ HYDRATION + NUTRITION:                                    │
  │   → Oral fluids early; IV if NPO                         │
  │   → Ensure bowel/bladder emptying                        │
  │ PAIN MANAGEMENT:                                          │
  │   → Adequate multimodal analgesia (inadequate pain = delirium)│
  │   → Avoid meperidine (normeperidine → neurotoxic)        │
  │ MEDICATION REVIEW:                                        │
  │   → Stop: Anticholinergics, benzodiazepines, antihistamines│
  │   → Reduce polypharmacy                                   │
  └───────────────────────────────────────────────────────────┘

Pharmacological Management

HYPERACTIVE DELIRIUM (agitated, endangering patient):
  ↓
FIRST: Identify and treat cause (pain, urinary retention, hypoxia, metabolic)
  ↓
NON-PHARMACOLOGICAL: Reorientation, calm environment, family presence
  ↓
IF STILL SEVERE / UNSAFE (falling, pulling lines):

HALOPERIDOL (First-generation antipsychotic - most evidence):
  → 0.5-1 mg PO/IM (elderly: start low)
  → Maximum: 3-5 mg/24hr in elderly
  → Monitor QTc (risk of TdP if QTc > 500 ms)
  → Avoid in: Parkinson's disease, Lewy body dementia (extreme rigidity/NMS)

ATYPICAL ANTIPSYCHOTICS (alternatives - less extrapyramidal effects):
  → Quetiapine 12.5-25 mg PO BD (preferred in Parkinson's disease)
  → Olanzapine 2.5-5 mg PO/IM (more sedating)
  → Risperidone 0.5-1 mg PO

BENZODIAZEPINES (AVOID in most POD - worsen delirium):
  → USE ONLY FOR:
    • Alcohol withdrawal delirium (chlordiazepoxide, diazepam - FIRST LINE)
    • Benzodiazepine withdrawal delirium
    • Seizures
  → Lorazepam 0.5-1 mg IV for acute agitation when antipsychotics failed

MELATONIN / RAMELTEON:
  → Sleep-wake cycle restoration
  → 0.5-2 mg at night
  → Some evidence for prevention (not treatment)
  → Safe, minimal side effects

DEXMEDETOMIDINE (ICU delirium):
  → Emerging evidence for agitated ICU delirium
  → Reduces duration of delirium vs benzodiazepines in ICU
  → 0.2-0.7 mcg/kg/hr infusion

HYPOACTIVE DELIRIUM:
  → NO pharmacological treatment indicated in most cases
  → Risk of sedation making it worse
  → Focus on non-pharmacological and treating underlying cause

---

Prevention of POD (MOST IMPORTANT)

• Awaken patient daily (SAT - Spontaneous Awakening Trial)
• Breathing trial daily (SBT - Spontaneous Breathing Trial)
• Choice of sedation (dexmedetomidine > benzodiazepine)
• Delirium monitoring (CAM-ICU q shift)
• Early mobilization
• Family engagement

• Regional anesthesia preferred over GA in elderly (for hip fracture, TAVI, etc.)
• Dexmedetomidine infusion reduces delirium vs midazolam/propofol in ICU
• Ketamine (sub-anesthetic) may reduce POD in some studies
• Avoid meperidine (normeperidine accumulation → myoclonus, seizures, delirium)
• Avoid benzodiazepines as premedication in elderly (use gabapentin/dexmedetomidine instead)
• Depth of anesthesia: Avoid excessively deep anesthesia (BIS-guided GA)
• Hypotension prevention: Maintain cerebral perfusion (MAP > 65 mmHg)
• Rapid emergence: Avoid residual anesthetic + NMB

---

QUESTION 10A: Deep Hypothermic Circulatory Arrest (DHCA)

Definition

• Aortic arch surgery (aneurysm, dissection)
• Complex congenital heart surgery (infants and children - transposition, hypoplastic left heart)
• Giant intracranial aneurysms (rarely, neurosurgery)
• Descending aortic surgery with arch involvement

---

Physiological Basis

METABOLIC RATE AND TEMPERATURE:
  Q10 rule: For every 10°C drop in temperature, metabolic rate halves
  
  Normal (37°C): CMRO₂ = 3.5 mL/100g/min, O₂ stores last ~3-4 min
  20°C: CMRO₂ ≈ 0.5 mL/100g/min (reduced by ~85%)
  18°C: O₂ stores last ~45-60 minutes (safe circulatory arrest time)
  
  Safe DHCA time:
    ≤18°C: 30-45 minutes (without cerebral perfusion adjuncts)
    With adjuncts: Up to 60-90 minutes

---

Technique

Phases of DHCA

PHASE 1: COOLING (On CPB)
  → Full heparinization (300-400 U/kg; ACT > 400 sec)
  → Initiate CPB (aorta cannulation + RA/bicaval cannulation)
  → Cool via heat exchanger: Target ≤18°C (nasopharyngeal, esophageal, rectal temp)
  → Surface cooling: Ice bags to head, cooling blanket
  → Minimum cooling time: 20-30 min (ensure brain equilibration)
  → EEG monitoring: Aim for ELECTROCEREBRAL SILENCE (ECS) before arrest
  → THIOPENTONE 15-30 mg/kg IV (burst suppression before arrest - brain protection)
  → METHYLPREDNISOLONE 30 mg/kg (anti-inflammatory; reduces reperfusion injury)
  → MANNITOL 0.5 g/kg (osmotic protection)
  → Head positioning and external head cooling

PHASE 2: CIRCULATORY ARREST
  → Stop CPB
  → Remove blood from aortic cannula (retrograde exsanguination)
  → Surgeon operates on bloodless arch
  → EEG silent (confirming cerebral metabolic depression)
  → Perfusionist monitors time from arrest

PHASE 3: REPERFUSION AND REWARMING
  → Resume CPB
  → Gradual rewarming (≤0.5°C/min - prevents cerebral hyperthermia)
  → Target nasopharyngeal < 37°C (avoid hyperthermia - worsens neurological injury)
  → Cardiac defibrillation if VF on rewarming
  → Modified ultrafiltration (MUF) in pediatrics - removes excess fluid

---

Cerebral Protection Adjuncts (Extend Safe Arrest Time)

1. Antegrade Cerebral Perfusion (ACP) - Preferred

  → Cannulate right axillary artery OR bilateral carotid arteries
  → Continue perfusion to brain during systemic arrest
  → Flow: 10-15 mL/kg/min at lower temperature
  → Pressure: Maintain cerebral perfusion pressure
  → Extends safe arrest time to > 60 min
  → Provides direct oxygenation to brain
  → Preferred in most modern centers for complex arch surgery

2. Retrograde Cerebral Perfusion (RCP)

  → Retrograde flow via superior vena cava
  → Pressure: 20-25 mmHg (higher → cerebral edema)
  → Cold oxygenated blood flushes brain
  → Less effective than ACP (most blood shunts through non-brain vessels)
  → Advantage: Simple setup, flushes emboli

3. Hypothermia Alone (Profound DHCA - ≤18°C)

• Adequate for < 30 minutes without perfusion adjuncts
• Simple but limited arrest time

---

Pharmacological Brain Protection

---

pH Management Strategies

---

Complications of DHCA

NEUROLOGICAL (Most important):
  → Stroke (air/particle emboli, inadequate perfusion)
  → Neurocognitive dysfunction (subtle deficits - memory, executive function)
  → Transient neurological dysfunction (TND) - delayed emergence, confusion
  → Seizures

COAGULOPATHY:
  → Profound coagulopathy on rewarming (hypothermia + CPB)
  → Fibrinolysis, platelet dysfunction
  → Treatment: FFP, cryo, platelets, TXA, rFVIIa

CARDIAC:
  → Ventricular dysfunction post-arrest
  → Arrhythmias (AF on rewarming - common)
  → IABP / LVAD if low output

INFLAMMATORY:
  → SIRS response after CPB + arrest
  → Capillary leak, ARDS, AKI

PULMONARY:
  → Impaired surfactant (hypothermia + CPB)
  → ARDS, prolonged ventilation

---

QUESTION 10B: Newer Modes of Ventilation

Overview

---

Classification

CONVENTIONAL MODES:
  → Volume-Controlled Ventilation (VCV)
  → Pressure-Controlled Ventilation (PCV)
  → Synchronized Intermittent Mandatory Ventilation (SIMV)
  → Pressure Support Ventilation (PSV)

NEWER / ADVANCED MODES:
  1. PRVC (Pressure Regulated Volume Control)
  2. APRV (Airway Pressure Release Ventilation)
  3. HFOV (High-Frequency Oscillatory Ventilation)
  4. NAVA (Neurally Adjusted Ventilatory Assist)
  5. PAV / PAV+ (Proportional Assist Ventilation)
  6. Adaptive Support Ventilation (ASV)
  7. HFT (High-Flow Therapy via nasal cannula)
  8. AVAPS (Average Volume-Assured Pressure Support)

---

1. PRVC (Pressure Regulated Volume Control)

• Also called: VC+, Autoflow, Adaptive Pressure Ventilation (different names by different manufacturers)
• Principle: Dual-control mode - combines benefits of VCV (guaranteed volume) + PCV (decelerating flow)
• How it works: Ventilator delivers PCV breaths but automatically adjusts driving pressure breath-by-breath to achieve the set target tidal volume
• Advantages: Guaranteed tidal volume + lower peak airway pressures (vs VCV) + better patient comfort
• Clinical use: Most modern ICU ventilators default to this mode; excellent for ARDS (lung protective)

---

2. APRV (Airway Pressure Release Ventilation)

CONCEPT:
  Patient breathes spontaneously at HIGH continuous airway pressure (CPAP = P_High)
  Periodically, pressure is BRIEFLY RELEASED to P_Low
  → Release allows CO₂ clearance
  → Rapid return to P_High maintains alveolar recruitment

SETTINGS:
  P_High: 20-30 cmH₂O (near or slightly above Pmean in conventional ARDS ventilation)
  P_Low: 0-5 cmH₂O
  T_High: Long (4-6 seconds) - most time at P_High
  T_Low: Very short (0.4-0.8 seconds) - release duration

ADVANTAGES:
  → Keeps lung RECRUITED throughout breathing cycle
  → Spontaneous breathing maintained → Better VQ matching
  → Lower sedation requirement (patient breathes spontaneously)
  → Better hemodynamics (preserved spontaneous breathing → less ↓ venous return)
  → Prevents diaphragm atrophy

CLINICAL USE:
  → ARDS (early, mild-moderate) when conventional lung-protective fails
  → Trauma (ALI)
  → Post-cardiac surgery
  
LIMITATIONS:
  → Complex weaning process
  → Not suitable for severe ARDS (spontaneous effort may worsen VILI - P-SILI)
  → Difficult to use with high minute ventilation requirements

---

3. HFOV (High-Frequency Oscillatory Ventilation)

PRINCIPLE:
  Delivers VERY SMALL tidal volumes (1-4 mL/kg) at VERY HIGH FREQUENCIES (3-15 Hz)
  → Mean airway pressure (MAP) maintained CONSTANT (lung kept open)
  → Gas exchange by oscillations (NOT bulk flow convection)
  
  Gas transport mechanisms (HFOV):
    → Asymmetric velocity profiles
    → Taylor dispersion
    → Pendelluft (gas exchange between lung units)
    → Molecular diffusion (dominant near alveoli)

SETTINGS:
  → Frequency: 3-6 Hz (adults), 5-15 Hz (neonates)
  → Mean airway pressure (mPaw): 5 cmH₂O above CPAP needed for recruitment
  → Amplitude (Power): Controls ΔP → Controls tidal volume (CO₂ clearance)
  → FiO₂: Adjusted for oxygenation

ADVANTAGES:
  → Ultra-lung-protective (tiny TV)
  → Maintains constant mPaw → Lung always recruited
  → No overdistension (small ΔV)
  → Reduces VALI theoretically

CLINICAL USE:
  → Refractory ARDS (PaO₂/FiO₂ < 100) after failing conventional ventilation
  → Neonatal RDS (first-line in many units)
  → VACTERL association, congenital diaphragmatic hernia (neonates)

LIMITATIONS:
  → OSCAR and OSCILLATE trials (2013): No mortality benefit over conventional in adult ARDS; OSCILLATE stopped early (↑ harm with HFOV in adults!)
  → Deep sedation + NMB required (no patient triggering)
  → No breath-stacking alarm (desaturation can be insidious)
  → Currently used as rescue mode in adults; standard in neonates

---

4. NAVA (Neurally Adjusted Ventilatory Assist)

PRINCIPLE:
  Ventilator uses ELECTRICAL ACTIVITY OF THE DIAPHRAGM (EAdi) signal
  to trigger and size each breath - completely controlled by patient's
  own respiratory drive

HOW IT WORKS:
  Special NG tube with electrode array → Picks up EAdi signal
  EAdi signal → Triggers ventilator
  Larger EAdi → Larger assist delivered (proportional)
  Patient's neural drive controls both timing AND magnitude of ventilator support

ADVANTAGES:
  → Perfect patient-ventilator SYNCHRONY (no trigger delay)
  → Eliminates double-triggering, auto-cycling, reverse triggering
  → Preserves respiratory variability (more physiological)
  → Allows comfortable breathing with minimal sedation
  → Protects diaphragm from both atrophy and overload

CLINICAL USE:
  → Difficult-to-synchronize patients (high drive, high respiratory rate)
  → Weaning from ventilator
  → Neonates (particularly suitable - very sensitive to trigger delays)
  → COPD patients (air trapping makes conventional triggering difficult)

LIMITATIONS:
  → Requires specialized NG tube (EAdi catheter) - expensive
  → Cannot be used if diaphragm denervated or paralyzed (NMB)
  → EAdi signal may be difficult to obtain in some patients

---

5. PAV+ (Proportional Assist Ventilation Plus)

• Principle: Ventilator provides PROPORTIONAL assistance matching patient's effort (measures respiratory mechanics in real time)
• Benefit: Better synchrony; patient "drives" ventilator
• Use: Weaning, spontaneous breathing modes
• Available on Puritan Bennett 980 (PAV+)

---

6. Adaptive Support Ventilation (ASV)

• Principle: Closed-loop ventilation - ventilator automatically adjusts rate, TV, and pressure based on patient's measured lung mechanics (time constant)
• Uses Otis minimal work-of-breathing equation
• Goal: Minimize work of breathing at any given minute ventilation target
• Advantage: Automatic weaning transition (ASV guides from full support → spontaneous)
• Clinical use: Post-cardiac surgery patients; excellent for routine weaning

---

7. AVAPS (Average Volume-Assured Pressure Support)

• Setting: Non-invasive (BiPAP) mode
• Principle: Automatically adjusts inspiratory pressure to achieve target TV over time
• Clinical use: Obesity hypoventilation syndrome (OHS), COPD with hypercapnia
• Provides more consistent volume delivery vs standard BiPAP

---

8. High-Flow Nasal Cannula (HFNC) Oxygen Therapy

PRINCIPLE:
  Delivers heated, humidified O₂/air at high flows (30-60 L/min) via wide-bore nasal cannula
  Creates:
    → Continuous low-level CPAP (2-7 cmH₂O at 60 L/min)
    → Washes out nasopharyngeal dead space (CO₂ clearance)
    → Reduces work of breathing
    → Better mucociliary clearance (warm, humidified gas)

ADVANTAGES:
  → More comfortable than face mask or standard NIV
  → Allows eating, speaking, physiotherapy
  → Reduces reintubation rates post-extubation (Hernandez et al., JAMA 2016)
  → Reduces post-operative hypoxemia

CLINICAL APPLICATIONS:
  → Post-extubation hypoxia (moderate risk patients)
  → Immunocompromised patients with respiratory failure (avoids intubation)
  → Pre-oxygenation before intubation in ICU (apneic oxygenation)
  → Mild-moderate acute hypoxemic respiratory failure
  → Post-cardiac surgery (early extubation support)

LIMITATIONS:
  → Cannot deliver precise CPAP (variable with mouth breathing)
  → Not suitable for hypercapnic failure (insufficient CO₂ clearance)
  → Delays intubation if patient deteriorating (must watch closely)
  → FiO₂ estimation imprecise at high flows

FLOW SETTING GUIDANCE:
  Start: 30-40 L/min, FiO₂ 50-60%
  Up-titrate: To 60 L/min based on SpO₂ and comfort
  FiO₂: Titrate to SpO₂ 92-96%
  Monitor: ROX index (SpO₂/FiO₂ ÷ RR) - ROX > 4.88 at 12 hr predicts NIV/HFNC success

---

Summary: Newer Ventilation Modes

---

Quick Navigation Index - Paper 2